16844790	153	Liggett SB	A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.	Proceedings of the National Academy of Sciences of the United States of America	2006	112
19234451	153	Dorsch S	Analysis of receptor oligomerization by FRAP microscopy.	Nature methods	2009	73
8256857	177	Brett J	Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.	The American journal of pathology	1993	148
11723063	177	Bierhaus A	Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.	Diabetes	2001	155
12495433	177	Yonekura H	Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.	The Biochemical journal	2003	128
15142859	177	Burke AP	Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study.	Arteriosclerosis, thrombosis, and vascular biology	2004	91
16894049	177	Goldin A	Advanced glycation end products: sparking the development of diabetic vascular injury.	Circulation	2006	298
18089847	177	Hudson BI	Identification, classification, and expression of RAGE gene splice variants.	FASEB journal 	2008	79
22211895	177	Ramasamy R	Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications.	Annals of the New York Academy of Sciences	2011	59
26311460	177	Stinghen AE	Uremic Toxicity of Advanced Glycation End Products in CKD.	Journal of the American Society of Nephrology 	2016	16
10194466	183	Wallukat G	Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor.	The Journal of clinical investigation	1999	152
10699153	183	Kim S	Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.	Pharmacological reviews	2000	150
11937178	183	Dahl√∂f B	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.	Lancet	2002	438
12171785	183	Brasier AR	Vascular inflammation and the renin-angiotensin system.	Arteriosclerosis, thrombosis, and vascular biology	2002	86
15302780	183	de Zeeuw D	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.	Circulation	2004	99
15718497	183	Jaffe IZ	Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.	Circulation research	2005	78
15734615	183	Wachtell K	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.	Journal of the American College of Cardiology	2005	77
15919782	183	Wolf G	From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy.	Diabetes	2005	124
16324688	183	Mehta JL	Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders.	Cardiovascular research	2006	84
17452499	183	Wang M	Proinflammatory profile within the grossly normal aged human aortic wall.	Hypertension	2007	74
17588946	183	Martin MM	The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding.	The Journal of biological chemistry	2007	88
18579813	183	Brooke BS	Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.	The New England journal of medicine	2008	156
18607402	183	Dronavalli S	The pathogenesis of diabetic nephropathy.	Nature clinical practice. Endocrinology and metabolism	2008	93
19050008	183	Sun Y	Myocardial repair/remodelling following infarction: roles of local factors.	Cardiovascular research	2009	57
19145003	183	Parving HH	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.	Nephrology, dialysis, transplantation 	2009	51
20040868	183	Wang M	Arterial aging: a journey into subclinical arterial disease.	Current opinion in nephrology and hypertension	2010	47
20234356	183	Briet M	Aldosterone: effects on the kidney and cardiovascular system.	Nature reviews. Nephrology	2010	50
20393193	183	Malpas SC	Sympathetic nervous system overactivity and its role in the development of cardiovascular disease.	Physiological reviews	2010	117
20819950	183	de Cavanagh EM	Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?	Cardiovascular research	2011	35
21035950	183	Saavedra JM	Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.	Psychoneuroendocrinology	2011	45
21242487	183	Birks EJ	Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study.	Circulation	2011	45
21310411	183	Zhu N	Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration.	Atherosclerosis	2011	63
21670228	183	Goossens GH	Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation.	Circulation	2011	53
22922412	183	McCurley A	Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.	Nature medicine	2012	63
23643589	183	Youn JY	Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase.	Journal of molecular and cellular cardiology	2013	30
24144355	183	Schiffrin EL	Immune mechanisms in hypertension and vascular injury.	Clinical science	2014	39
24776703	183	Jiang F	Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.	Nature reviews. Cardiology	2014	24
25421983	183	Li W	Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension.	Hypertension	2015	19
25767285	183	Hall JE	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.	Circulation research	2015	52
26116691	183	Lin X	Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.	Journal of the American Heart Association	2015	24
26585673	183	Nagpal V	MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis.	Circulation	2016	13
15879332	185	Schrader J	Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).	Stroke	2005	66
17255528	185	Bogdarina I	Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension.	Circulation research	2007	97
12642050	197	Ketteler M	Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.	Lancet	2003	124
15375022	197	Moe SM	Pathophysiology of vascular calcification in chronic kidney disease.	Circulation research	2004	79
15504939	197	Reynolds JL	Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.	Journal of the American Society of Nephrology 	2004	140
19029462	197	Weikert C	Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke.	Circulation	2008	58
22426755	197	Montonen J	Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress.	European journal of nutrition	2013	26
23337953	197	Stefan N	The role of hepatokines in metabolism.	Nature reviews. Endocrinology	2013	33
25711438	197	Kapustin AN	Vascular smooth muscle cell calcification is mediated by regulated exosome secretion.	Circulation research	2015	36
26908770	197	Brandenburg VM	Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry.	Nephrology, dialysis, transplantation 	2017	7
10625301	207	Kim I	Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.	Circulation research	2000	128
10948069	207	van Nieuw Amerongen GP	Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases.	Circulation research	2000	99
11029403	207	Haynes MP	Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells.	Circulation research	2000	92
11673836	207	Tuder RM	Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.	The Journal of pathology	2001	102
11696579	207	Du XL	Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site.	The Journal of clinical investigation	2001	165
12039858	207	Humar R	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.	FASEB journal 	2002	84
12446767	207	Ming XF	Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells.	Molecular and cellular biology	2002	94
12810615	207	Hambrecht R	Regular physical activity improves endothelial function in patients with coronary artery disease by increasing phosphorylation of endothelial nitric oxide synthase.	Circulation	2003	131
14713953	207	Miyauchi H	Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.	The EMBO journal	2004	76
15319269	207	Wolfrum S	Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.	Arteriosclerosis, thrombosis, and vascular biology	2004	98
15765134	207	Dorn GW 2nd	Protein kinase cascades in the regulation of cardiac hypertrophy.	The Journal of clinical investigation	2005	178
16428510	207	Qian DZ	Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.	Clinical cancer research 	2006	71
16636132	207	Khakoo AY	Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.	The Journal of experimental medicine	2006	181
16942488	207	Jia G	Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells.	Immunology and cell biology	2006	83
17082639	207	Kim KS	A novel role of hypoxia-inducible factor in cobalt chloride- and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells.	Journal of immunology	2006	62
17182864	207	Shiojima I	Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway.	Genes and development	2006	112
17204661	207	Minamino T	Vascular cell senescence: contribution to atherosclerosis.	Circulation research	2007	104
17627510	207	Maiese K	Mechanistic insights into diabetes mellitus and oxidative stress.	Current medicinal chemistry	2007	64
18701483	207	Schnell CR	Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.	Cancer research	2008	60
19265662	207	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	219
19344728	207	Lecour S	Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway?	Journal of molecular and cellular cardiology	2009	56
20110532	207	Chimenti I	Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice.	Circulation research	2010	176
20360245	207	Meloni M	Nerve growth factor promotes cardiac repair following myocardial infarction.	Circulation research	2010	49
21124782	207	Meng J	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.	PloS one	2010	51
21464307	207	Xie X	IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.	Proceedings of the National Academy of Sciences of the United States of America	2011	67
21974986	207	Otvos L Jr	Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.	BMC biotechnology	2011	36
22586279	207	Chokshi A	Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure.	Circulation	2012	49
23589885	207	Kucharzewska P	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2013	132
24285680	207	Uberti F	Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways.	The Journal of clinical endocrinology and metabolism	2014	28
24373826	207	Mancuso C	Ferulic acid: pharmacological and toxicological aspects.	Food and chemical toxicology 	2014	20
24813607	207	Naqvi N	A proliferative burst during preadolescence establishes the final cardiomyocyte number.	Cell	2014	58
25964336	207	Kuppusamy KT	Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
11524400	284	Kamihata H	Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines.	Circulation	2001	144
19815705	284	Falc√≥n BL	Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.	The American journal of pathology	2009	58
20554518	284	Fang X	Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1.	The Journal of biological chemistry	2010	65
21209923	284	Conroy AL	Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study.	PloS one	2010	44
21742796	284	Goel S	Normalization of the vasculature for treatment of cancer and other diseases.	Physiological reviews	2011	282
22919072	284	Robson A	Uterine natural killer cells initiate spiral artery remodeling in human pregnancy.	FASEB journal 	2012	38
23136042	284	Huh D	A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice.	Science translational medicine	2012	76
23165704	284	Chen CW	Human pericytes for ischemic heart repair.	Stem cells	2013	45
23390563	284	Rufaihah AJ	Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity.	American journal of translational research	2013	32
23972477	284	Brudno Y	Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors.	Biomaterials	2013	34
10974057	335	Navab M	Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.	Journal of lipid research	2000	92
11705484	335	Tounian P	Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study.	Lancet	2001	103
14600188	335	Nissen SE	Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.	JAMA	2003	285
15314690	335	Zheng L	Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.	The Journal of clinical investigation	2004	165
16330696	335	Steyn K	Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study.	Circulation	2005	79
16452169	335	Ajees AA	Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases.	Proceedings of the National Academy of Sciences of the United States of America	2006	64
16629855	335	Walldius G	The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.	Journal of internal medicine	2006	70
17284700	335	Nicholls SJ	Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.	JAMA	2007	91
17699012	335	Singh IM	High-density lipoprotein as a therapeutic target: a systematic review.	JAMA	2007	87
18261682	335	van der Steeg WA	High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.	Journal of the American College of Cardiology	2008	56
18323573	335	Bloedon LT	Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.	Journal of lipid research	2008	96
18519851	335	Kastelein JJ	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.	Circulation	2008	65
18711012	335	Mora S	Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.	Circulation	2008	64
18719109	335	Shao B	Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I.	Proceedings of the National Academy of Sciences of the United States of America	2008	56
19802338	335	Chasman DI	Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication.	Circulation. Cardiovascular genetics	2008	50
20466975	335	Fryirs MA	Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.	Arteriosclerosis, thrombosis, and vascular biology	2010	42
20581677	335	Kontush A	Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.	Current opinion in lipidology	2010	45
20847045	335	Lewis TL	Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.	The Journal of biological chemistry	2010	44
21068008	335	Watson CE	Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.	Journal of lipid research	2011	46
21226578	335	Khera AV	Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.	The New England journal of medicine	2011	401
21399642	335	Huang R	Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma.	Nature structural and molecular biology	2011	56
22219194	335	Shao B	Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions.	The Journal of biological chemistry	2012	45
22797450	335	Emerging Risk Factors Collaboration.	Lipid-related markers and cardiovascular disease prediction.	JAMA	2012	51
23965489	335	Boekholdt SM	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.	Circulation	2013	30
24002795	335	Mora S	High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.	Circulation	2013	44
24464187	335	Huang Y	An abundant dysfunctional apolipoprotein A1 in human atheroma.	Nature medicine	2014	46
25062744	335	Joshi PH	Association of high-density lipoprotein subclasses and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies.	European journal of preventive cardiology	2016	13
26025389	335	Saleheen D	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.	The lancet. Diabetes and endocrinology	2015	45
27431356	335	O'Donnell MJ	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.	Lancet	2016	28
3670400	338	McLean JW	cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.	Nature	1987	161
16000355	338	Tsimikas S	Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.	The New England journal of medicine	2005	108
16476102	338	Barter PJ	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.	Journal of internal medicine	2006	68
17215532	338	Cuchel M	Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.	The New England journal of medicine	2007	79
17938300	338	Tabas I	Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.	Circulation	2007	236
18223541	338	Williams KJ	Rapid regression of atherosclerosis: insights from the clinical and experimental literature.	Nature clinical practice. Cardiovascular medicine	2008	65
18458145	338	Fonseca VA	Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.	Diabetes care	2008	51
18832751	338	Shaw JA	Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque.	Circulation research	2008	64
19153411	338	El Harchaoui K	High-density lipoprotein particle size and concentration and coronary risk.	Annals of internal medicine	2009	61
19204302	338	Mora S	Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.	Circulation	2009	101
19329177	338	Ridker PM	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.	Lancet	2009	161
19698799	338	Curcio CA	Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins.	Progress in retinal and eye research	2009	81
20220185	338	Ladenson PW	Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia.	The New England journal of medicine	2010	57
21226665	338	Tsimikas S	Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease.	Current pharmaceutical design	2011	38
21357823	338	Hermansson A	Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice.	Circulation	2011	39
21849529	338	Stanhope KL	Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women.	The Journal of clinical endocrinology and metabolism	2011	60
22653811	338	Cayo MA	JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia.	Hepatology	2012	31
22898069	338	Tsimikas S	Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.	Journal of the American College of Cardiology	2012	39
23122790	338	Tsimikas S	Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.	Journal of the American College of Cardiology	2012	39
23351925	338	Anderson TJ	2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.	The Canadian journal of cardiology	2013	141
23704675	338	TODAY Study Group.	Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial.	Diabetes care	2013	26
24013058	338	Thomas GS	Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.	Journal of the American College of Cardiology	2013	30
24623100	338	Fenzl A	Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals.	Diabetologia	2014	37
25082583	338	Boekholdt SM	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.	Journal of the American College of Cardiology	2014	32
25555214	338	Fabbrini E	Metabolically normal obese people are protected from adverse effects following weight gain.	The Journal of clinical investigation	2015	30
26210642	338	Tsimikas S	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.	Lancet	2015	44
26361154	338	Capoulade R	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.	Journal of the American College of Cardiology	2015	25
3277611	348	Davignon J	Apolipoprotein E polymorphism and atherosclerosis.	Arteriosclerosis	1988	201
12558712	348	Haan MN	Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors.	Journal of the American Geriatrics Society	2003	97
12566949	348	Kuller LH	Risk factors for dementia in the cardiovascular health cognition study.	Neuroepidemiology	2003	86
14568809	348	Lopez OL	Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2.	Archives of neurology	2003	89
14728627	348	Fitzpatrick AL	Incidence and prevalence of dementia in the Cardiovascular Health Study.	Journal of the American Geriatrics Society	2004	103
15781953	348	Podewils LJ	Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study.	American journal of epidemiology	2005	133
16108925	348	Newman AB	Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort.	Journal of the American Geriatrics Society	2005	81
16216938	348	Kivipelto M	Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.	Archives of neurology	2005	215
16782234	348	Zipser BD	Microvascular injury and blood-brain barrier leakage in Alzheimer's disease.	Neurobiology of aging	2007	84
16786033	348	Martins IJ	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease.	Molecular psychiatry	2006	78
16820298	348	Hatters DM	Apolipoprotein E structure: insights into function.	Trends in biochemical sciences	2006	143
17332893	348	Vaisar T	Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.	The Journal of clinical investigation	2007	238
17515542	348	Bowman GL	Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.	Neurology	2007	55
18003940	348	Szekely CA	NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type.	Neurology	2008	57
18195144	348	Irie F	Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study.	Archives of neurology	2008	64
18203129	348	Jofre-Monseny L	Impact of apoE genotype on oxidative stress, inflammation and disease risk.	Molecular nutrition and food research	2008	68
18349428	348	Calder√≥n-Garcidue√±as L	Long-term air pollution exposure is associated with neuroinflammation, an altered innate immune response, disruption of the blood-brain barrier, ultrafine particulate deposition, and accumulation of amyloid beta-42 and alpha-synuclein in children and young adults.	Toxicologic pathology	2008	103
18378884	348	Vernooij MW	Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.	Neurology	2008	117
18448847	348	Anstey KJ	Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis.	The American journal of geriatric psychiatry 	2008	88
19106071	348	Mahley RW	Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS.	Journal of lipid research	2009	106
19319544	348	Bell RD	Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.	Acta neuropathologica	2009	186
19671905	348	F√©art C	Adherence to a Mediterranean diet, cognitive decline, and risk of dementia.	JAMA	2009	102
20031276	348	Rasgon NL	Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease.	Neurobiology of aging	2011	41
20032288	348	Roe CM	Cancer linked to Alzheimer disease but not vascular dementia.	Neurology	2010	47
20155424	348	Grinberg LT	Vascular pathology in the aged human brain.	Acta neuropathologica	2010	61
20864661	348	Zhu YC	Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study.	Stroke	2010	48
20876479	348	Poels MM	Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.	Stroke	2010	76
21060014	348	Carmichael O	Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.	Archives of neurology	2010	72
21307170	348	Poels MM	Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study.	Stroke	2011	44
22095980	348	Averill MM	S100A8 and S100A9 in cardiovascular biology and disease.	Arteriosclerosis, thrombosis, and vascular biology	2012	34
22972646	348	Lo RY	Vascular burden and Alzheimer disease pathologic progression.	Neurology	2012	47
23601373	348	Bangen KJ	APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.	Journal of stroke and cerebrovascular diseases 	2013	27
23670794	348	Mart√≠nez-Lapiscina EH	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial.	Journal of neurology, neurosurgery, and psychiatry	2013	39
24910016	348	Bu XL	A study on the association between infectious burden and Alzheimer's disease.	European journal of neurology	2015	16
25633388	348	Marioni RE	DNA methylation age of blood predicts all-cause mortality in later life.	Genome biology	2015	114
26354483	348	Jaunmuktane Z	Evidence for human transmission of amyloid-Œ≤ pathology and cerebral amyloid angiopathy.	Nature	2015	41
26791201	348	Theendakara V	Direct Transcriptional Effects of Apolipoprotein E.	The Journal of neuroscience 	2016	13
26863354	348	Satizabal CL	Incidence of Dementia over Three Decades in the Framingham Heart Study.	The New England journal of medicine	2016	56
9989963	717	de Lorgeril M	Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.	Circulation	1999	252
17557426	717	Redline S	The scoring of respiratory events in sleep: reliability and validity.	Journal of clinical sleep medicine 	2007	72
21486813	717	Sato K	The distribution of blood flow in the carotid and vertebral arteries during dynamic exercise in humans.	The Journal of physiology	2011	40
22495584	717	Willie CK	Regional brain blood flow in man during acute changes in arterial blood gases.	The Journal of physiology	2012	84
23615880	717	Wang W	Glycine metabolism in animals and humans: implications for nutrition and health.	Amino acids	2013	42
25190741	717	Verbree J	Assessment of middle cerebral artery diameter during hypocapnia and hypercapnia in humans using ultra-high-field MRI.	Journal of applied physiology	2014	31
4057091	966	Andersen P	Maximal perfusion of skeletal muscle in man.	The Journal of physiology	1985	208
9624661	966	-	American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults.	Medicine and science in sports and exercise	1998	280
10811742	966	Wilkinson IB	The influence of heart rate on augmentation index and central arterial pressure in humans.	The Journal of physiology	2000	114
12570944	966	Manjunath G	Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community.	Journal of the American College of Cardiology	2003	107
15954913	966	Tonelli M	Biomarkers of inflammation and progression of chronic kidney disease.	Kidney international	2005	74
16253727	966	Gelber RP	Association between body mass index and CKD in apparently healthy men.	American journal of kidney diseases 	2005	73
17309916	966	Briguori C	Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.	Circulation	2007	59
17660025	966	Chonchol M	Relationship of uric acid with progression of kidney disease.	American journal of kidney diseases 	2007	71
18295053	966	Zhang L	Prevalence and factors associated with CKD: a population study from Beijing.	American journal of kidney diseases 	2008	55
18337481	966	Weiner DE	Uric acid and incident kidney disease in the community.	Journal of the American Society of Nephrology 	2008	75
19303683	966	Madero M	Uric acid and long-term outcomes in CKD.	American journal of kidney diseases 	2009	65
19332353	966	Krum H	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.	Lancet	2009	258
19559169	966	Wilhelm-Leen ER	Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey.	The American journal of medicine	2009	64
19909994	966	Andropoulos DB	Brain immaturity is associated with brain injury before and after neonatal cardiac surgery with high-flow bypass and cerebral oxygenation monitoring.	The Journal of thoracic and cardiovascular surgery	2010	51
20138414	966	White SL	Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.	American journal of kidney diseases 	2010	56
20170948	966	Bakris GL	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.	Lancet	2010	50
20172445	966	Stevens LA	Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP).	American journal of kidney diseases 	2010	56
20441712	966	Black C	Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.	Health technology assessment	2010	43
20884698	966	Di Angelantonio E	Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.	BMJ	2010	44
21098347	966	Roussel R	Metformin use and mortality among patients with diabetes and atherothrombosis.	Archives of internal medicine	2010	47
22206742	966	Jotwani V	Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.	American journal of kidney diseases 	2012	31
22337679	966	Thadhani R	Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.	JAMA	2012	90
22614980	966	Jones LW	Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.	Journal of clinical oncology 	2012	47
22770927	966	Roshanravan B	A prospective study of frailty in nephrology-referred patients with CKD.	American journal of kidney diseases 	2012	46
23022429	966	Wong CJ	CKiD (CKD in children) prospective cohort study: a review of current findings.	American journal of kidney diseases 	2012	30
23111824	966	Hallan SI	Age and association of kidney measures with mortality and end-stage renal disease.	JAMA	2012	95
23360717	966	Nitsch D	Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis.	BMJ	2013	44
23489677	966	Dobre M	Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.	American journal of kidney diseases 	2013	33
23782649	966	Worthley SG	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.	European heart journal	2013	35
24092942	966	Blood Pressure Lowering Treatment Trialists' Collaboration.	Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.	BMJ	2013	29
24902920	966	Ambrosius WT	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).	Clinical trials	2014	47
25393378	966	Naik RP	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.	JAMA	2014	23
25552421	966	Udell JA	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.	Diabetes care	2015	19
25562264	966	Livingstone SJ	Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.	JAMA	2015	32
26038534	966	Molnar MZ	Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.	Thorax	2015	17
26337133	966	Grams ME	Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.	American journal of kidney diseases 	2016	19
9151786	1003	Zhou Y	Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?	The Journal of clinical investigation	1997	162
9625748	1003	Esser S	Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells.	Journal of cell science	1998	157
10648408	1003	Peichev M	Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.	Blood	2000	409
11157668	1003	Gill M	Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells.	Circulation research	2001	132
11401930	1003	Shintani S	Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.	Circulation	2001	156
11416160	1003	Hendrix MJ	Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.	Proceedings of the National Academy of Sciences of the United States of America	2001	97
11490021	1003	Shaw SK	Real-time imaging of vascular endothelial-cadherin during leukocyte transmigration across endothelium.	Journal of immunology	2001	88
11827993	1003	Reyes M	Origin of endothelial progenitors in human postnatal bone marrow.	The Journal of clinical investigation	2002	179
12615796	1003	Rehman J	Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors.	Circulation	2003	318
14699017	1003	Hur J	Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis.	Arteriosclerosis, thrombosis, and vascular biology	2004	207
15345218	1003	Wang L	Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties.	Immunity	2004	107
15533859	1003	Wojakowski W	Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction.	Circulation	2004	73
16115630	1003	Kooistra MR	Epac1 regulates integrity of endothelial cell junctions through VE-cadherin.	FEBS letters	2005	108
16141364	1003	Weksler BB	Blood-brain barrier-specific properties of a human adult brain endothelial cell line.	FASEB journal 	2005	269
16524930	1003	Zengin E	Vascular wall resident progenitor cells: a source for postnatal vasculogenesis.	Development	2006	104
17967785	1003	Traktuev DO	A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks.	Circulation research	2008	205
18195090	1003	Birdsey GM	Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.	Blood	2008	69
18258663	1003	F√∂rster C	Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier.	The Journal of physiology	2008	59
18420943	1003	Schulz B	ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin.	Circulation research	2008	58
18776942	1003	Murakami M	The FGF system has a key role in regulating vascular integrity.	The Journal of clinical investigation	2008	77
19658191	1003	Alvero AB	Stem-like ovarian cancer cells can serve as tumor vascular progenitors.	Stem cells	2009	56
19875721	1003	Nourse MB	VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering.	Arteriosclerosis, thrombosis, and vascular biology	2010	43
21876760	1003	Uosaki H	Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression.	PloS one	2011	77
22326223	1003	Tran KV	The vascular endothelium of the adipose tissue gives rise to both white and brown fat cells.	Cell metabolism	2012	81
23520160	1003	Li J	Conversion of human fibroblasts to functional endothelial cells by defined factors.	Arteriosclerosis, thrombosis, and vascular biology	2013	37
24992685	1003	Rochfort KD	Downregulation of blood-brain barrier phenotype by proinflammatory cytokines involves NADPH oxidase-dependent ROS generation: consequences for interendothelial adherens and tight junctions.	PloS one	2014	24
25956031	1003	Good RB	Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension.	The American journal of pathology	2015	21
14559957	1071	Barzilai N	Unique lipoprotein phenotype and genotype associated with exceptional longevity.	JAMA	2003	157
15925013	1071	Ginsberg HN	Regulation of plasma triglycerides in insulin resistance and diabetes.	Archives of medical research	2005	78
17387129	1071	Nissen SE	Effect of torcetrapib on the progression of coronary atherosclerosis.	The New England journal of medicine	2007	149
17630038	1071	Bots ML	Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.	Lancet	2007	65
17984165	1071	Barter PJ	Effects of torcetrapib in patients at high risk for coronary events.	The New England journal of medicine	2007	476
18536749	1071	Forrest MJ	Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.	British journal of pharmacology	2008	57
19436720	1071	Xie L	Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.	PLoS computational biology	2009	79
20031564	1071	Ridker PM	Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study.	Circulation. Cardiovascular genetics	2009	61
20400780	1071	Musunuru K	Candidate gene association resource (CARe): design, methods, and proof of concept.	Circulation. Cardiovascular genetics	2010	89
20838585	1071	Smith EN	Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study.	PLoS genetics	2010	47
22089718	1071	Nicholls SJ	Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.	JAMA	2011	70
22344176	1071	Zhang L	Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein.	Nature chemical biology	2012	36
22345126	1071	L√ºscher TF	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.	European heart journal	2012	34
23126252	1071	Schwartz GG	Effects of dalcetrapib in patients with a recent acute coronary syndrome.	The New England journal of medicine	2012	274
25038074	1071	Keene D	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.	BMJ	2014	38
25541553	1071	Agha G	Adiposity is associated with DNA methylation profile in adipose tissue.	International journal of epidemiology	2015	15
3594774	1351	White HD	Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.	Circulation	1987	221
6407019	1351	Edgell CJ	Permanent cell line expressing human factor VIII-related antigen established by hybridization.	Proceedings of the National Academy of Sciences of the United States of America	1983	311
11723017	1351	Heitzer T	Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.	Circulation	2001	256
11956120	1351	Wannamethee SG	Physical activity and hemostatic and inflammatory variables in elderly men.	Circulation	2002	83
14688693	1351	Prasad SM	The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures.	The Journal of thoracic and cardiovascular surgery	2003	83
14769624	1351	Wassertheil-Smoller S	Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI).	Archives of internal medicine	2004	103
15159263	1351	Hu G	Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.	Archives of internal medicine	2004	123
15547162	1351	Devereux RB	Prognostic significance of left ventricular mass change during treatment of hypertension.	JAMA	2004	104
15590763	1351	Foley RN	Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.	Journal of the American Society of Nephrology 	2005	165
16300480	1351	Martin-Ruiz CM	Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study.	Aging cell	2005	78
17640394	1351	Howe LR	Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.	Breast cancer research 	2007	81
17928595	1351	Ford I	Long-term follow-up of the West of Scotland Coronary Prevention Study.	The New England journal of medicine	2007	71
18378618	1351	Schramm TK	Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.	Circulation	2008	72
18596250	1351	Terracciano A	Personality predictors of longevity: activity, emotional stability, and conscientiousness.	Psychosomatic medicine	2008	64
19012918	1351	Huang WC	Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?	The Journal of urology	2009	108
19131355	1351	Wizemann V	The mortality risk of overhydration in haemodialysis patients.	Nephrology, dialysis, transplantation 	2009	86
19161884	1351	Budoff MJ	Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (Multi-Ethnic Study of Atherosclerosis).	Journal of the American College of Cardiology	2009	62
19221219	1351	Fung TT	Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women.	Circulation	2009	126
20498416	1351	Rutten FH	Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.	Archives of internal medicine	2010	51
21168019	1351	Damiano RJ Jr	The Cox maze IV procedure: predictors of late recurrence.	The Journal of thoracic and cardiovascular surgery	2011	37
23446902	1351	Sch√∂ttker B	Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study.	The American journal of clinical nutrition	2013	45
24192549	1351	Maegele M	An update on the coagulopathy of trauma.	Shock	2014	20
26384521	1351	Kovesdy CP	Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.	Circulation	2015	22
27074389	1351	Twig G	Body-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood.	The New England journal of medicine	2016	21
9077376	1401	Ridker PM	Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.	The New England journal of medicine	1997	538
9655393	1401	Staels B	Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.	Nature	1998	144
9727541	1401	Ridker PM	Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.	Circulation	1998	187
9892589	1401	Koenig W	C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.	Circulation	1999	209
9987089	1401	Zimmermann J	Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.	Kidney international	1999	125
10231453	1401	Stenvinkel P	Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.	Kidney international	1999	158
10335721	1401	Harris TB	Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.	The American journal of medicine	1999	307
10411845	1401	Ridker PM	Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.	Circulation	1999	119
10525563	1401	Seaton A	Particulate air pollution and the blood.	Thorax	1999	98
10591334	1401	Visser M	Elevated C-reactive protein levels in overweight and obese adults.	JAMA	1999	334
10733371	1401	Ridker PM	C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.	The New England journal of medicine	2000	789
10769275	1401	Ridker PM	Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.	Circulation	2000	363
10807470	1401	Gottdiener JS	Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study.	Journal of the American College of Cardiology	2000	198
11056086	1401	Pasceri V	Direct proinflammatory effect of C-reactive protein on human endothelial cells.	Circulation	2000	195
11063384	1401	Loos BG	Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients.	Journal of periodontology	2000	101
11157411	1401	Geffken DF	Association between physical activity and markers of inflammation in a healthy elderly population.	American journal of epidemiology	2001	99
11238260	1401	Zwaka TP	C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.	Circulation	2001	97
11282915	1401	Ridker PM	High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.	Circulation	2001	143
11430324	1401	Ridker PM	Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.	The New England journal of medicine	2001	153
11434828	1401	Albert MA	Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.	JAMA	2001	174
11440492	1401	Peters A	Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study.	European heart journal	2001	103
11466099	1401	Pradhan AD	C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.	JAMA	2001	700
11574423	1401	Barzilay JI	The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.	Diabetes	2001	88
11577954	1401	Noack B	Periodontal infections contribute to elevated systemic C-reactive protein level.	Journal of periodontology	2001	91
11673759	1401	Festa A	The relation of body fat mass and distribution to markers of chronic inflammation.	International journal of obesity and related metabolic disorders 	2001	107
11692019	1401	Rost NS	Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.	Stroke	2001	105
11739301	1401	Chung MK	C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation.	Circulation	2001	196
11744348	1401	Das UN	Is obesity an inflammatory condition?	Nutrition	2001	122
11748099	1401	Wallace AM	Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).	Circulation	2001	123
11864854	1401	Liu S	Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women.	The American journal of clinical nutrition	2002	95
11877368	1401	Libby P	Inflammation and atherosclerosis.	Circulation	2002	957
11916939	1401	Stehouwer CD	Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.	Diabetes	2002	94
12034649	1401	Shamsuzzaman AS	Elevated C-reactive protein in patients with obstructive sleep apnea.	Circulation	2002	138
12163427	1401	Haffner SM	Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.	Circulation	2002	90
12190368	1401	Pradhan AD	Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.	JAMA	2002	98
12210786	1401	Schmidt R	Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.	Annals of neurology	2002	132
12213876	1401	Ramsay JE	Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways.	The Journal of clinical endocrinology and metabolism	2002	103
12234944	1401	Venugopal SK	Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells.	Circulation	2002	99
12366601	1401	Blake GJ	Inflammatory bio-markers and cardiovascular risk prediction.	Journal of internal medicine	2002	90
12390945	1401	H√ºrlimann D	Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.	Circulation	2002	84
12432042	1401	Ridker PM	Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.	The New England journal of medicine	2002	500
12515748	1401	Shlipak MG	Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.	Circulation	2003	125
12576356	1401	Enright PL	The 6-min walk test: a quick measure of functional status in elderly adults.	Chest	2003	114
12615790	1401	Yokoe T	Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.	Circulation	2003	134
12654609	1401	Sin DD	Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease.	Circulation	2003	169
12684358	1401	Esposito K	Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.	JAMA	2003	222
12752838	1401	Rantanen T	Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism.	Journal of the American Geriatrics Society	2003	105
12821543	1401	Pischon T	Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women.	Circulation	2003	94
12904517	1401	Manson JE	Estrogen plus progestin and the risk of coronary heart disease.	The New England journal of medicine	2003	240
12943870	1401	Cesari M	Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition Health ABC Study).	The American journal of cardiology	2003	80
14530185	1401	Naghavi M	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.	Circulation	2003	322
14557340	1401	Naghavi M	From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.	Circulation	2003	153
14568895	1401	Cesari M	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study.	Circulation	2003	180
14573731	1401	Brennan ML	Prognostic value of myeloperoxidase in patients with chest pain.	The New England journal of medicine	2003	140
14623805	1401	Aviles RJ	Inflammation as a risk factor for atrial fibrillation.	Circulation	2003	212
14665655	1401	Sesso HD	C-reactive protein and the risk of developing hypertension.	JAMA	2003	141
14747502	1401	Liu Y	Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition.	JAMA	2004	107
14871421	1401	Oberg BP	Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.	Kidney international	2004	127
14871913	1401	Seddon JM	Association between C-reactive protein and age-related macular degeneration.	JAMA	2004	95
14871914	1401	Jiang R	Body iron stores in relation to risk of type 2 diabetes in apparently healthy women.	JAMA	2004	99
14975482	1401	Meier-Ewert HK	Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk.	Journal of the American College of Cardiology	2004	229
14996776	1401	Nissen SE	Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.	JAMA	2004	214
15051634	1401	Ridker PM	Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores.	Circulation	2004	70
15082700	1401	Pischon T	Plasma adiponectin levels and risk of myocardial infarction in men.	JAMA	2004	303
15136311	1401	Ford DE	Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey.	Archives of internal medicine	2004	94
15173056	1401	Willerson JT	Inflammation as a cardiovascular risk factor.	Circulation	2004	159
15173060	1401	Landmesser U	Endothelial function: a critical determinant in atherosclerosis?	Circulation	2004	114
15175438	1401	Weiss R	Obesity and the metabolic syndrome in children and adolescents.	The New England journal of medicine	2004	476
15197140	1401	Esposito K	Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.	Circulation	2004	73
15197153	1401	Ridker PM	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?	Circulation	2004	82
15207950	1401	McCarey DW	Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.	Lancet	2004	115
15209648	1401	Penninx BW	Inflammatory markers and incident mobility limitation in the elderly.	Journal of the American Geriatrics Society	2004	83
15234425	1401	Chrysohoou C	Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study.	Journal of the American College of Cardiology	2004	90
15262830	1401	Selvin E	Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.	Circulation	2004	263
15262834	1401	Rutter MK	C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.	Circulation	2004	103
15337754	1401	Black S	C-reactive Protein.	The Journal of biological chemistry	2004	186
15447916	1401	Lopez-Garcia E	Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction.	The American journal of clinical nutrition	2004	141
15536110	1401	Yaffe K	The metabolic syndrome, inflammation, and risk of cognitive decline.	JAMA	2004	197
15572589	1401	Ferrucci L	The origins of age-related proinflammatory state.	Blood	2005	184
15602020	1401	Pai JK	Inflammatory markers and the risk of coronary heart disease in men and women.	The New England journal of medicine	2004	233
15635109	1401	Ridker PM	C-reactive protein levels and outcomes after statin therapy.	The New England journal of medicine	2005	246
15635110	1401	Nissen SE	Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.	The New England journal of medicine	2005	137
15660291	1401	Reiner AP	Population structure, admixture, and aging-related phenotypes in African American adults: the Cardiovascular Health Study.	American journal of human genetics	2005	66
15699278	1401	Desvarieux M	Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).	Circulation	2005	111
15710760	1401	Reilly MP	Resistin is an inflammatory marker of atherosclerosis in humans.	Circulation	2005	144
15817606	1401	Wannamethee SG	Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease.	European heart journal	2005	69
15827312	1401	Shlipak MG	Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors.	JAMA	2005	152
15855252	1401	Karelis AD	The metabolically healthy but obese individual presents a favorable inflammation profile.	The Journal of clinical endocrinology and metabolism	2005	115
15897982	1401	Carlson CS	Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels.	American journal of human genetics	2005	89
15941879	1401	Noakes M	Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women.	The American journal of clinical nutrition	2005	66
15955978	1401	Seddon JM	Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers.	Archives of ophthalmology	2005	90
15992651	1401	Arad Y	Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study.	Journal of the American College of Cardiology	2005	136
16002815	1401	Fung TT	Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction.	The American journal of clinical nutrition	2005	118
16030277	1401	Ridker PM	Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.	JAMA	2005	136
16053959	1401	Khera A	Race and gender differences in C-reactive protein levels.	Journal of the American College of Cardiology	2005	145
16087797	1401	Tzoulaki I	C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study.	Circulation	2005	79
16219884	1401	Fibrinogen Studies Collaboration.	Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.	JAMA	2005	201
16234304	1401	Ferrucci L	Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers.	The Journal of clinical endocrinology and metabolism	2006	121
16251237	1401	Kang DH	Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.	Journal of the American Society of Nephrology 	2005	147
16251239	1401	Fried LF	Kidney function as a predictor of noncardiovascular mortality.	Journal of the American Society of Nephrology 	2005	78
16267155	1401	Shlipak MG	Cystatin C and mortality risk in the elderly: the health, aging, and body composition study.	Journal of the American Society of Nephrology 	2006	66
16277583	1401	Loos BG	Systemic markers of inflammation in periodontitis.	Journal of periodontology	2005	79
16293802	1401	R√ºckerl R	Air pollution and markers of inflammation and coagulation in patients with coronary heart disease.	American journal of respiratory and critical care medicine	2006	110
16330181	1401	Alley DE	Socioeconomic status and C-reactive protein levels in the US population: NHANES IV.	Brain, behavior, and immunity	2006	62
16377395	1401	Honda H	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.	American journal of kidney diseases 	2006	72
16458170	1401	Shaw LJ	Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.	Journal of the American College of Cardiology	2006	89
16600925	1401	Ma Y	Association between dietary fiber and serum C-reactive protein.	The American journal of clinical nutrition	2006	65
16631001	1401	Klem I	Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging.	Journal of the American College of Cardiology	2006	77
16642000	1401	Pepys MB	Targeting C-reactive protein for the treatment of cardiovascular disease.	Nature	2006	121
16738034	1401	Man SF	C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.	Thorax	2006	74
16738067	1401	McDade TW	Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging, and social relations study.	Psychosomatic medicine	2006	96
16784934	1401	Ferrario CM	Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.	The American journal of cardiology	2006	95
16818923	1401	Estruch R	Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial.	Annals of internal medicine	2006	198
16901505	1401	von K√§nel R	Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder.	Journal of psychiatric research	2007	84
16923436	1401	Lakoski SG	Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort.	American heart journal	2006	64
16926254	1401	Vega GL	Influence of body fat content and distribution on variation in metabolic risk.	The Journal of clinical endocrinology and metabolism	2006	76
17040956	1401	Wang Y	Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.	Clinical chemistry	2007	91
17043079	1401	Fitzpatrick AL	Leukocyte telomere length and cardiovascular disease in the cardiovascular health study.	American journal of epidemiology	2007	200
17095717	1401	Lee DS	Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.	Arteriosclerosis, thrombosis, and vascular biology	2007	81
17101857	1401	Crawford DC	Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey.	Circulation	2006	60
17158434	1401	Esmaillzadeh A	Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome.	The American journal of clinical nutrition	2006	81
17164456	1401	Lange LA	Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events.	JAMA	2006	65
17182988	1401	Wang TJ	Multiple biomarkers for the prediction of first major cardiovascular events and death.	The New England journal of medicine	2006	238
17192290	1401	Stewart FM	Longitudinal assessment of maternal endothelial function and markers of inflammation and placental function throughout pregnancy in lean and obese mothers.	The Journal of clinical endocrinology and metabolism	2007	59
17192343	1401	Samaras K	Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and corrected hypoadiponectinemia.	Diabetes care	2007	61
17225957	1401	Pollitt RA	Early-life and adult socioeconomic status and inflammatory risk markers in adulthood.	European journal of epidemiology	2007	62
17242319	1401	Ranjit N	Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis.	Archives of internal medicine	2007	66
17310862	1401	Punjabi NM	C-reactive protein is associated with sleep disordered breathing independent of adiposity.	Sleep	2007	59
17324119	1401	Savoia C	Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.	Clinical science	2007	72
17329698	1401	Tonetti MS	Treatment of periodontitis and endothelial function.	The New England journal of medicine	2007	166
17341558	1401	Balagopal P	Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation.	The Journal of clinical endocrinology and metabolism	2007	61
17389308	1401	Jefferson AL	Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.	Neurology	2007	64
17420420	1401	Barzilay JI	Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study.	Archives of internal medicine	2007	76
17452738	1401	Uribarri J	Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging.	The journals of gerontology. Series A, Biological sciences and medical sciences	2007	82
17494805	1401	Yanbaeva DG	Systemic effects of smoking.	Chest	2007	152
17502528	1401	Dhingra R	Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.	Archives of internal medicine	2007	171
17524614	1401	Frey DJ	The effects of 40 hours of total sleep deprivation on inflammatory markers in healthy young adults.	Brain, behavior, and immunity	2007	71
17531663	1401	Ridker PM	C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.	Journal of the American College of Cardiology	2007	119
17533210	1401	Wilson PW	Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.	Archives of internal medicine	2007	216
17541022	1401	Kiechl S	Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.	Arteriosclerosis, thrombosis, and vascular biology	2007	62
17556718	1401	Drager LF	Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea.	American journal of respiratory and critical care medicine	2007	93
17576871	1401	Cao JJ	Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study.	Circulation	2007	65
17637925	1401	R√ºckerl R	Air pollution and inflammation (interleukin-6, C-reactive protein, fibrinogen) in myocardial infarction survivors.	Environmental health perspectives	2007	71
17679132	1401	Pradhan AD	Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.	The American journal of medicine	2007	56
17701281	1401	Kanbay M	Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions.	International urology and nephrology	2007	71
17702268	1401	Taheri S	Correlates of serum C-reactive protein (CRP)--no association with sleep duration or sleep disordered breathing.	Sleep	2007	60
17911176	1401	Laughlin GA	Low serum testosterone and mortality in older men.	The Journal of clinical endocrinology and metabolism	2008	119
17923467	1401	Ahn SG	Relationship of epicardial adipose tissue by echocardiography to coronary artery disease.	Heart	2008	56
17967770	1401	Mora S	Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms.	Circulation	2007	133
17984166	1401	Kjekshus J	Rosuvastatin in older patients with systolic heart failure.	The New England journal of medicine	2007	151
18166598	1401	Fabbri LM	Complex chronic comorbidities of COPD.	The European respiratory journal	2008	97
18180395	1401	Wang TJ	Vitamin D deficiency and risk of cardiovascular disease.	Circulation	2008	497
18240558	1401	Ridker PM	Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.	Nutrition reviews	2007	59
18256376	1401	Szeto CC	Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.	Clinical journal of the American Society of Nephrology 	2008	52
18294231	1401	Paraskevas S	A systematic review and meta-analyses on C-reactive protein in relation to periodontitis.	Journal of clinical periodontology	2008	77
18376000	1401	Kastelein JJ	Simvastatin with or without ezetimibe in familial hypercholesterolemia.	The New England journal of medicine	2008	172
18385206	1401	Astor BC	Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.	American journal of epidemiology	2008	72
18391129	1401	Danese A	Elevated inflammation levels in depressed adults with a history of childhood maltreatment.	Archives of general psychiatry	2008	126
18413553	1401	Fung TT	Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women.	Archives of internal medicine	2008	170
18439548	1401	Ridker PM	Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study.	American journal of human genetics	2008	114
18452784	1401	Bahrami H	Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study.	Journal of the American College of Cardiology	2008	84
18480203	1401	Zethelius B	Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.	The New England journal of medicine	2008	179
18574092	1401	Dobnig H	Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality.	Archives of internal medicine	2008	271
18625666	1401	Dorkova Z	Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome.	Chest	2008	64
18629312	1401	Delfino RJ	Circulating biomarkers of inflammation, antioxidant activity, and platelet activation are associated with primary combustion aerosols in subjects with coronary artery disease.	Environmental health perspectives	2008	95
18765397	1401	Serruys PW	Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.	Circulation	2008	89
18843258	1401	Ravani P	Vitamin D levels and patient outcome in chronic kidney disease.	Kidney international	2009	85
18997194	1401	Ridker PM	C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.	Circulation	2008	142
18997196	1401	Ridker PM	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.	The New England journal of medicine	2008	930
19075102	1401	Liu PY	Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.	Circulation	2009	53
19131384	1401	de Ruijter W	Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.	BMJ	2009	70
19153409	1401	Paynter NP	Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3.	Annals of internal medicine	2009	73
19196644	1401	Brinkley TE	Chronic inflammation is associated with low physical function in older adults across multiple comorbidities.	The journals of gerontology. Series A, Biological sciences and medical sciences	2009	69
19240794	1401	van Leeuwen WM	Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP.	PloS one	2009	82
19387353	1401	Triant VA	Association of C-reactive protein and HIV infection with acute myocardial infarction.	Journal of acquired immune deficiency syndromes	2009	99
19416750	1401	Stewart JC	A prospective evaluation of the directionality of the depression-inflammation relationship.	Brain, behavior, and immunity	2009	65
19424218	1401	Mozaffarian D	Health effects of trans-fatty acids: experimental and observational evidence.	European journal of clinical nutrition	2009	60
19443637	1401	de Boer IH	25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification.	Journal of the American Society of Nephrology 	2009	69
19449008	1401	Packard RR	Innate and adaptive immunity in atherosclerosis.	Seminars in immunopathology	2009	45
19470939	1401	Pierce BL	Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.	Journal of clinical oncology 	2009	147
19477372	1401	Zakynthinos E	Inflammatory biomarkers in coronary artery disease.	Journal of cardiology	2009	47
19520972	1401	Eisenhardt SU	Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques.	Circulation research	2009	46
19567439	1401	Melander O	Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.	JAMA	2009	114
19584191	1401	Nadeau KJ	Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity.	The Journal of clinical endocrinology and metabolism	2009	46
19630828	1401	Ridker PM	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).	Journal of thrombosis and haemostasis 	2009	71
19695853	1401	Balducci S	Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss.	Nutrition, metabolism, and cardiovascular diseases 	2010	80
19712036	1401	Ross AC	Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.	Clinical infectious diseases 	2009	75
19805772	1401	Helfand M	Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force.	Annals of internal medicine	2009	62
20016471	1401	Barreto DV	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.	Kidney international	2010	51
20082925	1401	Matthews KA	Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?	Journal of the American College of Cardiology	2009	85
20097779	1401	Bertoni AG	Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA).	Diabetes care	2010	50
20176986	1401	Mora S	Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.	Circulation	2010	44
20181810	1401	Bakker GC	An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach.	The American journal of clinical nutrition	2010	42
20394901	1401	Rogers IS	Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina.	JACC. Cardiovascular imaging	2010	52
20417247	1401	Shelton RC	Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression.	Progress in neurobiology	2010	47
20497981	1401	Blankenberg S	Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.	Circulation	2010	60
20516377	1401	Fraser A	Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood.	Circulation	2010	107
20538833	1401	Goicoechea M	Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.	Clinical journal of the American Society of Nephrology 	2010	124
20569726	1401	Soliman EZ	Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).	American heart journal	2010	46
20605303	1401	Shafi T	Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.	American journal of kidney diseases 	2010	42
20628408	1401	Velho S	Metabolically healthy obesity: different prevalences using different criteria.	European journal of clinical nutrition	2010	45
20682604	1401	Upadhyay A	Inflammation, kidney function and albuminuria in the Framingham Offspring cohort.	Nephrology, dialysis, transplantation 	2011	38
20921964	1401	Harvie MN	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.	International journal of obesity	2011	75
21200002	1401	Anderson TJ	Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study.	Circulation	2011	55
21216812	1401	Myasoedova E	Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.	Annals of the rheumatic diseases	2011	61
21224291	1401	Healy GN	Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06.	European heart journal	2011	249
21232666	1401	Stamatakis E	Screen-based entertainment time, all-cause mortality, and cardiovascular events: population-based study with ongoing mortality and hospital events follow-up.	Journal of the American College of Cardiology	2011	72
21252259	1401	Sandler NG	Plasma levels of soluble CD14 independently predict mortality in HIV infection.	The Journal of infectious diseases	2011	346
21257787	1401	Allen RW	An air filter intervention study of endothelial function among healthy adults in a woodsmoke-impacted community.	American journal of respiratory and critical care medicine	2011	38
21525259	1401	Azadbakht L	The Dietary Approaches to Stop Hypertension eating plan affects C-reactive protein, coagulation abnormalities, and hepatic function tests among type 2 diabetic patients.	The Journal of nutrition	2011	40
21534675	1401	Shankar A	Loneliness, social isolation, and behavioral and biological health indicators in older adults.	Health psychology 	2011	52
21542910	1401	Carson V	Volume, patterns, and types of sedentary behavior and cardio-metabolic health in children and adolescents: a cross-sectional study.	BMC public health	2011	44
21616287	1401	Fallah-Rad N	The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.	Journal of the American College of Cardiology	2011	62
21718915	1401	Al Mheid I	Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans.	Journal of the American College of Cardiology	2011	62
21791456	1401	Andersen LB	Physical activity and cardiovascular risk factors in children.	British journal of sports medicine	2011	41
21792295	1401	Kones R	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.	Drug design, development and therapy	2011	39
21835901	1401	Colish J	Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI.	Chest	2012	32
21856482	1401	Blaha MJ	Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study.	Lancet	2011	59
21982649	1401	Ridker PM	Interleukin-1Œ≤ inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).	American heart journal	2011	165
22237295	1401	Bind MA	Air pollution and markers of coagulation, inflammation, and endothelial function: associations and epigene-environment interactions in an elderly cohort.	Epidemiology	2012	67
22367431	1401	Jenny NS	Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars.	The journals of gerontology. Series A, Biological sciences and medical sciences	2012	38
22431676	1401	Kavousi M	Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study.	Annals of internal medicine	2012	57
22492856	1401	Parrinello CM	Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women.	The Journal of infectious diseases	2012	41
22508708	1401	Hamer M	Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality.	The Journal of clinical endocrinology and metabolism	2012	79
22708923	1401	Bartlett DB	The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection.	Aging cell	2012	31
22738663	1401	Yan S	The expanding burden of cardiometabolic risk in China: the China Health and Nutrition Survey.	Obesity reviews 	2012	40
22749178	1401	Bogdanski P	Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients.	Nutrition research	2012	36
22819432	1401	Ballantyne CM	Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).	The American journal of cardiology	2012	35
22820791	1401	Subramanian S	Arterial inflammation in patients with HIV.	JAMA	2012	122
22889633	1401	Johnson GH	Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials.	Journal of the Academy of Nutrition and Dietetics	2012	31
22891048	1401	Hamer M	Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study.	Circulation	2012	34
22907935	1401	Wang TJ	Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.	Circulation	2012	66
22910756	1401	Yeboah J	Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals.	JAMA	2012	143
23022122	1401	DeBoer MD	Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions.	Nutrition	2013	34
23034020	1401	Emerging Risk Factors Collaboration.	C-reactive protein, fibrinogen, and cardiovascular disease prediction.	The New England journal of medicine	2012	172
23129601	1401	Ridker PM	Effects of interleukin-1Œ≤ inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.	Circulation	2012	76
23141484	1401	Yamamoto S	Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.	Journal of the American College of Cardiology	2012	37
23143785	1401	Gupta SC	Therapeutic roles of curcumin: lessons learned from clinical trials.	The AAPS journal	2013	133
23171381	1401	Choi J	Obesity and C-reactive protein in various populations: a systematic review and meta-analysis.	Obesity reviews 	2013	69
23428789	1401	Miller BJ	C-reactive protein levels in schizophrenia: a review and meta-analysis.	Clinical schizophrenia and related psychoses	2014	26
23500256	1401	Khoury M	Role of the waist/height ratio in the cardiometabolic risk assessment of children classified by body mass index.	Journal of the American College of Cardiology	2013	26
23612048	1401	Vogelzangs N	Anxiety disorders and inflammation in a large adult cohort.	Translational psychiatry	2013	49
23633760	1401	Grandner MA	Extreme sleep durations and increased C-reactive protein: effects of sex and ethnoracial group.	Sleep	2013	35
23689826	1401	Varadhan R	Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults.	The journals of gerontology. Series A, Biological sciences and medical sciences	2014	26
23844064	1401	Gary T	Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients.	PloS one	2013	26
24107546	1401	Shivappa N	A population-based dietary inflammatory index predicts levels of C-reactive protein in the Seasonal Variation of Blood Cholesterol Study (SEASONS).	Public health nutrition	2014	75
24154724	1401	Rook GA	Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24284436	1401	Ley SH	Associations between red meat intake and biomarkers of inflammation and glucose metabolism in women.	The American journal of clinical nutrition	2014	22
24425829	1401	Deelen J	Leukocyte telomere length associates with prospective mortality independent of immune-related parameters and known genetic markers.	International journal of epidemiology	2014	28
24488982	1401	Kim EJ	Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging.	Circulation. Cardiovascular imaging	2014	21
24819981	1401	Semba RD	Resveratrol levels and all-cause mortality in older community-dwelling adults.	JAMA internal medicine	2014	22
24864079	1401	Ridker PM	Anti-inflammatory therapies for cardiovascular disease.	European heart journal	2014	40
24970784	1401	Dregan A	Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study.	Circulation	2014	25
25142571	1401	Irwin MR	Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial.	Sleep	2014	25
25274000	1401	Xanthakis V	Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study.	Circulation	2014	24
25341516	1401	Guarner V	Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease.	Interdisciplinary topics in gerontology	2015	22
25447616	1401	Parthasarathy S	Persistent insomnia is associated with mortality risk.	The American journal of medicine	2015	21
25577441	1401	Emami H	Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans.	JACC. Cardiovascular imaging	2015	31
25710246	1401	Hajat A	Long-term exposure to air pollution and markers of inflammation, coagulation, and endothelial activation: a repeat-measures analysis in the Multi-Ethnic Study of Atherosclerosis (MESA).	Epidemiology	2015	21
25827033	1401	Michopoulos V	Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma.	The American journal of psychiatry	2015	23
25835438	1401	Puri R	Impact of statins on serial coronary calcification during atheroma progression and regression.	Journal of the American College of Cardiology	2015	25
25965853	1401	Dopico XC	Widespread seasonal gene expression reveals annual differences in human immunity and physiology.	Nature communications	2015	40
26117398	1401	Vlachopoulos C	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society.	Atherosclerosis	2015	31
27013319	1401	Odegaard AO	Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes.	Cardiovascular diabetology	2016	16
27040132	1401	Yusuf S	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.	The New England journal of medicine	2016	24
9393975	1432	Rousseau S	p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells.	Oncogene	1997	155
10604986	1432	Kol A	Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells.	Journal of immunology	2000	102
12639843	1432	Birukov KG	Magnitude-dependent regulation of pulmonary endothelial cell barrier function by cyclic stretch.	American journal of physiology. Lung cellular and molecular physiology	2003	86
16198162	1432	Kaminska B	MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.	Biochimica et biophysica acta	2005	142
16385087	1432	Isoda K	Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.	Arteriosclerosis, thrombosis, and vascular biology	2006	72
17481747	1432	Cuenda A	p38 MAP-kinases pathway regulation, function and role in human diseases.	Biochimica et biophysica acta	2007	249
18021257	1432	Graichen R	Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK.	Differentiation; research in biological diversity	2008	50
19236889	1432	Siu ER	Cadmium-induced testicular injury.	Toxicology and applied pharmacology	2009	54
20110572	1432	Schwartz EA	Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation.	Arteriosclerosis, thrombosis, and vascular biology	2010	42
20150510	1432	Shi J	Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20643109	1432	Paine A	Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential.	Biochemical pharmacology	2010	135
21047517	1432	F√∂ldes G	Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?	Journal of molecular and cellular cardiology	2011	36
21144973	1432	Rajesh M	Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.	Journal of the American College of Cardiology	2010	56
21691084	1432	Molinari C	1Œ±,25-dihydroxycholecalciferol induces nitric oxide production in cultured endothelial cells.	Cellular physiology and biochemistry 	2011	37
22254000	1432	Vauzour D	Polyphenols and human health: prevention of disease and mechanisms of action.	Nutrients	2010	61
25666404	1432	B√§ck M	Anti-inflammatory therapies for atherosclerosis.	Nature reviews. Cardiology	2015	24
25799226	1432	Wu Y	Activation of AMPKŒ±2 in adipocytes is essential for nicotine-induced insulin resistance in vivo.	Nature medicine	2015	18
15327406	1471	Herget-Rosenthal S	Early detection of acute renal failure by serum cystatin C.	Kidney international	2004	155
15809461	1471	Sarnak MJ	Cystatin C concentration as a risk factor for heart failure in older adults.	Annals of internal medicine	2005	94
15901858	1471	Shlipak MG	Cystatin C and the risk of death and cardiovascular events among elderly persons.	The New England journal of medicine	2005	289
16908914	1471	Shlipak MG	Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.	Annals of internal medicine	2006	141
17190862	1471	Ix JH	Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.	Circulation	2007	74
17699320	1471	Furth SL	Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study.	Clinical journal of the American Society of Nephrology 	2006	104
18295055	1471	Stevens LA	Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.	American journal of kidney diseases 	2008	337
19001197	1471	Rifkin DE	Rapid kidney function decline and mortality risk in older adults.	Archives of internal medicine	2008	99
20709438	1471	Choi A	Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.	American journal of kidney diseases 	2010	43
21164029	1471	Peralta CA	Cystatin C identifies chronic kidney disease patients at higher risk for complications.	Journal of the American Society of Nephrology 	2011	62
22305758	1471	Astor BC	Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population.	American journal of kidney diseases 	2012	48
23470495	1471	Brouwers FP	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.	European heart journal	2013	54
24004120	1471	Shlipak MG	Cystatin C versus creatinine in determining risk based on kidney function.	The New England journal of medicine	2013	122
25599331	1471	Tang WH	Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.	Circulation research	2015	78
9651244	1482	Schott JJ	Congenital heart disease caused by mutations in the transcription factor NKX2-5.	Science	1998	221
10587520	1482	Benson DW	Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways.	The Journal of clinical investigation	1999	106
11431700	1482	Hiroi Y	Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation.	Nature genetics	2001	115
12242268	1482	Xu C	Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells.	Circulation research	2002	162
15109497	1482	Pashmforoush M	Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block.	Cell	2004	103
20723802	1482	Behfar A	Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction.	Journal of the American College of Cardiology	2010	62
21242485	1482	Mishra R	Characterization and functionality of cardiac progenitor cells in congenital heart patients.	Circulation	2011	67
22965990	1482	Kawamura M	Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model.	Circulation	2012	83
24255110	1482	Thavandiran N	Design and formulation of functional pluripotent stem cell-derived cardiac microtissues.	Proceedings of the National Academy of Sciences of the United States of America	2013	59
25082575	1482	Sanchez-Freire V	Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells.	Journal of the American College of Cardiology	2014	23
26875865	1482	Luna-Zurita L	Complex Interdependence Regulates Heterotypic Transcription Factor Distribution and Coordinates Cardiogenesis.	Cell	2016	12
15706079	1536	Van Buul JD	Expression and localization of NOX2 and NOX4 in primary human endothelial cells.	Antioxidants and redox signaling	2005	102
18783311	1536	Pendyala S	Role of Nox4 and Nox2 in hyperoxia-induced reactive oxygen species generation and migration of human lung endothelial cells.	Antioxidants and redox signaling	2009	67
20981034	1536	Touyz RM	Reactive oxygen species and vascular biology: implications in human hypertension.	Hypertension research 	2011	81
22405985	1536	Schramm A	Targeting NADPH oxidases in vascular pharmacology.	Vascular pharmacology	2012	42
22445098	1536	Montezano AC	Molecular mechanisms of hypertension--reactive oxygen species and antioxidants: a basic science update for the clinician.	The Canadian journal of cardiology	2012	43
22713144	1536	Montezano AC	Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies.	Annals of medicine	2012	41
23600794	1536	Montezano AC	Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.	Antioxidants and redox signaling	2014	29
24180474	1536	Konior A	NADPH oxidases in vascular pathology.	Antioxidants and redox signaling	2014	39
25066192	1536	Drummond GR	Endothelial NADPH oxidases: which NOX to target in vascular disease?	Trends in endocrinology and metabolism	2014	35
25564678	1536	Sullivan MN	Localized TRPA1 channel Ca2+ signals stimulated by reactive oxygen species promote cerebral artery dilation.	Science signaling	2015	19
25645978	1536	Cocks M	Sprint interval and moderate-intensity continuous training have equal benefits on aerobic capacity, insulin sensitivity, muscle capillarisation and endothelial eNOS/NAD(P)Hoxidase protein ratio in obese men.	The Journal of physiology	2016	12
19106083	1557	Simon T	Genetic determinants of response to clopidogrel and cardiovascular events.	The New England journal of medicine	2009	232
19106084	1557	Mega JL	Cytochrome p-450 polymorphisms and response to clopidogrel.	The New England journal of medicine	2009	286
19108880	1557	Collet JP	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.	Lancet	2009	126
19706858	1557	Shuldiner AR	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	JAMA	2009	239
20435227	1557	Ashley EA	Clinical assessment incorporating a personal genome.	Lancet	2010	227
20620727	1557	Hulot JS	Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.	Journal of the American College of Cardiology	2010	56
20801494	1557	Mega JL	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.	Lancet	2010	74
20801498	1557	Wallentin L	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.	Lancet	2010	83
20978260	1557	Mega JL	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.	JAMA	2010	145
20979470	1557	Par√© G	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.	The New England journal of medicine	2010	87
22088980	1557	Mega JL	Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.	JAMA	2011	51
22190063	1557	Delaney JT	Predicting clopidogrel response using DNA samples linked to an electronic health record.	Clinical pharmacology and therapeutics	2012	40
22203539	1557	Holmes MV	CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.	JAMA	2011	84
22464343	1557	Roberts JD	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.	Lancet	2012	52
23698643	1557	Scott SA	Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.	Clinical pharmacology and therapeutics	2013	96
8439223	1628	Stamler J	Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.	Archives of internal medicine	1993	134
17420405	1628	Pennestri MH	Nocturnal blood pressure changes in patients with restless legs syndrome.	Neurology	2007	62
18414631	1628	Auchincloss AH	Associations between recent exposure to ambient fine particulate matter and blood pressure in the Multi-ethnic Study of Atherosclerosis (MESA).	Environmental health perspectives	2008	85
18602635	1628	Lefevre M	Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals.	Atherosclerosis	2009	51
19144222	1628	Stroud LR	Stress response and the adolescent transition: performance versus peer rejection stressors.	Development and psychopathology	2009	114
22088239	1628	Liu LS	2010 Chinese guidelines for the management of hypertension.	Zhonghua xin xue guan bing za zhi	2011	95
23509172	1628	Parkinson JR	Preterm birth and the metabolic syndrome in adult life: a systematic review and meta-analysis.	Pediatrics	2013	35
23519910	1628	Asgary S	Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects.	Phytotherapy research 	2014	25
23680280	1628	Zhou JY	Neck circumference as an independent predictive contributor to cardio-metabolic syndrome.	Cardiovascular diabetology	2013	27
25775274	1628	Beveridge LA	Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data.	JAMA internal medicine	2015	35
27007693	1628	Nielson CM	Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations.	The Journal of clinical endocrinology and metabolism	2016	15
1463530	1636	SOLVD Investigators.	Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.	The New England journal of medicine	1992	239
7477219	1636	K√∏ber L	A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.	The New England journal of medicine	1995	132
8136829	1636	Sch√§chter F	Genetic associations with human longevity at the APOE and ACE loci.	Nature genetics	1994	146
8614419	1636	Packer M	The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.	The New England journal of medicine	1996	319
9217756	1636	-	Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)	Lancet	1997	153
9450756	1636	Eiserich JP	Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils.	Nature	1998	203
10030325	1636	Hansson L	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.	Lancet	1999	124
10675071	1636	-	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.	Lancet	2000	322
10716457	1636	Cohn JN	Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.	Journal of the American College of Cardiology	2000	303
10924499	1636	Tipnis SR	A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.	The Journal of biological chemistry	2000	198
10969042	1636	Donoghue M	A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.	Circulation research	2000	242
11130523	1636	Neal B	Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.	Lancet	2000	184
11181474	1636	Guerin AP	Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.	Circulation	2001	116
11356434	1636	Dargie HJ	Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.	Lancet	2001	123
11566918	1636	London GM	Arterial wave reflections and survival in end-stage renal failure.	Hypertension	2001	109
12020339	1636	Beckman JA	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.	JAMA	2002	339
12584366	1636	Wing LM	A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.	The New England journal of medicine	2003	95
12600911	1636	Hein S	Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms.	Circulation	2003	157
12759325	1636	Psaty BM	Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.	JAMA	2003	146
13678869	1636	McMurray JJ	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.	Lancet	2003	157
13678870	1636	Granger CB	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.	Lancet	2003	137
13678872	1636	Fox KM	Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).	Lancet	2003	185
14610160	1636	Pfeffer MA	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.	The New England journal of medicine	2003	214
14769700	1636	McAlister FA	Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.	Circulation	2004	92
15076798	1636	Pescatello LS	American College of Sports Medicine position stand. Exercise and hypertension.	Medicine and science in sports and exercise	2004	182
15516696	1636	Barnett AH	Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.	The New England journal of medicine	2004	109
15531767	1636	Braunwald E	Angiotensin-converting-enzyme inhibition in stable coronary artery disease.	The New England journal of medicine	2004	117
16760444	1636	Cooper WO	Major congenital malformations after first-trimester exposure to ACE inhibitors.	The New England journal of medicine	2006	115
16781387	1636	Mancini GB	Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.	Journal of the American College of Cardiology	2006	65
17336879	1636	Everett TH 4th	Atrial fibrosis and the mechanisms of atrial fibrillation.	Heart rhythm	2007	56
17765963	1636	Patel A	Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.	Lancet	2007	245
17970613	1636	Atlas SA	The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.	Journal of managed care pharmacy 	2007	67
17984484	1636	Matchar DB	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.	Annals of internal medicine	2008	63
18371492	1636	Ho PM	Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease.	American heart journal	2008	85
18378520	1636	ONTARGET Investigators.	Telmisartan, ramipril, or both in patients at high risk for vascular events.	The New England journal of medicine	2008	420
18707986	1636	Mann JF	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.	Lancet	2008	243
18757085	1636	Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.	Lancet	2008	132
19050195	1636	Kesselheim AS	Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.	JAMA	2008	61
19052124	1636	Jamerson K	Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.	The New England journal of medicine	2008	232
19597068	1636	Sink KM	Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study.	Archives of internal medicine	2009	48
20440277	1636	Ruggenenti P	The RAAS in the pathogenesis and treatment of diabetic nephropathy.	Nature reviews. Nephrology	2010	43
20486275	1636	Yu MA	Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction.	Journal of hypertension	2010	65
20625111	1636	Hsu DT	Enalapril in infants with single ventricle: results of a multicenter randomized trial.	Circulation	2010	43
21872920	1636	Yusuf S	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.	Lancet	2011	128
22124756	1636	Agarwal D	Chronic exercise modulates RAS components and improves balance between pro- and anti-inflammatory cytokines in the brain of SHR.	Basic research in cardiology	2011	36
22511654	1636	van Vark LC	Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients.	European heart journal	2012	51
23100218	1636	Ruggenenti P	Mechanisms and treatment of CKD.	Journal of the American Society of Nephrology 	2012	34
23414791	1636	Omland T	Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.	Journal of the American College of Cardiology	2013	30
24206457	1636	Fried LF	Combined angiotensin inhibition for the treatment of diabetic nephropathy.	The New England journal of medicine	2013	107
25399731	1636	Torres VE	Angiotensin blockade in late autosomal dominant polycystic kidney disease.	The New England journal of medicine	2014	25
25767283	1636	Te Riet L	Hypertension: renin-angiotensin-aldosterone system alterations.	Circulation research	2015	42
18425967	1803	Richter B	Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.	The Cochrane database of systematic reviews	2008	54
20075143	1803	Read PA	DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.	Circulation. Cardiovascular imaging	2010	42
20357375	1803	Fadini GP	The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.	Diabetes care	2010	63
21208359	1803	Madsbad S	An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.	Diabetes, obesity and metabolism	2011	36
21403054	1803	Bennett WL	Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.	Annals of internal medicine	2011	82
21593202	1803	Lamers D	Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.	Diabetes	2011	94
21734003	1803	Drucker DJ	The safety of incretin-based therapies--review of the scientific evidence.	The Journal of clinical endocrinology and metabolism	2011	40
21812507	1803	Baetta R	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.	Drugs	2011	39
22106978	1803	Monami M	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.	Current medical research and opinion	2011	41
22215383	1803	Monami M	DPP-4 inhibitors and lipids: systematic review and meta-analysis.	Advances in therapy	2012	38
22234149	1803	Johansen OE	Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.	Cardiovascular diabetology	2012	49
22323472	1803	Ussher JR	Cardiovascular biology of the incretin system.	Endocrine reviews	2012	96
22703861	1803	Patil HR	Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.	The American journal of cardiology	2012	36
22748821	1803	Gallwitz B	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.	Lancet	2012	69
22843705	1803	Kr√∂ller-Sch√∂n S	Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.	Cardiovascular research	2012	37
22925682	1803	Monami M	Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.	Diabetes, obesity and metabolism	2013	44
23296071	1803	Scheen AJ	Cardiovascular effects of gliptins.	Nature reviews. Cardiology	2013	27
23386232	1803	Matsubara J	Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.	Circulation journal 	2013	33
23449634	1803	Rosenstock J	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.	Diabetes and vascular disease research	2013	27
23525426	1803	Ayaori M	Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.	Journal of the American Heart Association	2013	31
23894014	1803	dos Santos L	Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.	Circulation. Heart failure	2013	26
23932846	1803	Aroor AR	Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.	Metabolism	2013	41
23992601	1803	Scirica BM	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.	The New England journal of medicine	2013	377
23992602	1803	White WB	Alogliptin after acute coronary syndrome in patients with type 2 diabetes.	The New England journal of medicine	2013	294
24375052	1803	Muskiet MH	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?	Nature reviews. Nephrology	2014	21
24732974	1803	DeMarco VG	The pathophysiology of hypertension in patients with obesity.	Nature reviews. Endocrinology	2014	43
24750644	1803	Wu S	Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.	Cardiovascular therapeutics	2014	28
24793580	1803	Monami M	Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.	Nutrition, metabolism, and cardiovascular diseases 	2014	30
24855202	1803	Ussher JR	Cardiovascular actions of incretin-based therapies.	Circulation research	2014	40
25074318	1803	Nakamura K	DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.	Cardiovascular diabetology	2014	23
25528528	1803	Savarese G	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.	International journal of cardiology	2015	17
25765696	1803	Zannad F	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.	Lancet	2015	67
26052984	1803	Green JB	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2015	183
26063450	1803	Ferrannini E	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.	European heart journal	2015	17
26112890	1803	Fadini GP	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.	European heart journal	2015	16
26457538	1803	Ou SM	Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.	Annals of internal medicine	2015	17
26489970	1803	Nauck M	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.	Diabetes, obesity and metabolism	2016	14
26628419	1803	Mita T	Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).	Diabetes care	2016	14
26822324	1803	Mita T	Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.	Diabetes care	2016	14
26888822	1803	Li L	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.	BMJ	2016	15
27007958	1803	Filion KB	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.	The New England journal of medicine	2016	19
27434443	1803	Palmer SC	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.	JAMA	2016	14
2649896	1906	Inoue A	The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.	Proceedings of the National Academy of Sciences of the United States of America	1989	247
8497283	1906	Giaid A	Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.	The New England journal of medicine	1993	200
15194177	1906	Barst RJ	Diagnosis and differential assessment of pulmonary arterial hypertension.	Journal of the American College of Cardiology	2004	114
16258029	1906	Larsen BT	Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.	American journal of physiology. Heart and circulatory physiology	2006	66
16618833	1906	Kim JA	Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.	Circulation	2006	269
17065335	1906	Schmid H	Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy.	Diabetes	2006	104
17179929	1906	Rask-Madsen C	Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes.	Nature clinical practice. Endocrinology and metabolism	2007	104
17242275	1906	Silver AE	Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress.	Circulation	2007	56
18256324	1906	Au P	Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature.	Blood	2008	138
18261470	1906	Wood KC	Sickle cell disease vasculopathy: a state of nitric oxide resistance.	Free radical biology and medicine	2008	53
18629317	1906	Peretz A	Diesel exhaust inhalation elicits acute vasoconstriction in vivo.	Environmental health perspectives	2008	59
19149564	1906	Potenza MA	Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.	Current medicinal chemistry	2009	61
19465546	1906	Donato AJ	Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase.	American journal of physiology. Heart and circulatory physiology	2009	73
19903865	1906	Chen S	Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells.	American journal of physiology. Endocrinology and metabolism	2010	49
21244363	1906	Seals DR	Aging and vascular endothelial function in humans.	Clinical science	2011	117
21683931	1906	D'haeseleer M	Vascular aspects of multiple sclerosis.	The Lancet. Neurology	2011	37
21940766	1906	Gabler NB	Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.	Chest	2012	30
23649149	1906	Kong P	The pathogenesis of cardiac fibrosis.	Cellular and molecular life sciences 	2014	93
23832699	1906	Ivashchenko CY	Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype.	American journal of physiology. Heart and circulatory physiology	2013	29
24046434	1906	Jaguszewski M	A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction.	European heart journal	2014	22
24951764	1906	Paulin R	The metabolic theory of pulmonary arterial hypertension.	Circulation research	2014	33
26711459	1906	Love S	Cerebrovascular disease in ageing and Alzheimer's disease.	Acta neuropathologica	2016	16
26956245	1906	Davenport AP	Endothelin.	Pharmacological reviews	2016	22
17082756	1956	Chonchol M	25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey.	Kidney international	2007	63
18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
19109410	1956	Graner MW	Proteomic and immunologic analyses of brain tumor exosomes.	FASEB journal 	2009	101
19421193	1956	Bos PD	Genes that mediate breast cancer metastasis to the brain.	Nature	2009	433
19429932	1956	Mirza MA	Relationship between circulating FGF23 and total body atherosclerosis in the community.	Nephrology, dialysis, transplantation 	2009	51
20018733	1956	Chan G	Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
20130423	1956	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	103
20189275	1956	Matsushita K	Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study.	American journal of kidney diseases 	2010	64
20671236	1956	Zhu WZ	Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.	Circulation research	2010	59
21355053	1956	Rosolowsky ET	Risk for ESRD in type 1 diabetes remains high despite renoprotection.	Journal of the American Society of Nephrology 	2011	52
21610077	1956	Kinney SM	Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes.	The Journal of biological chemistry	2011	46
21646496	1956	Alonso A	Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.	Circulation	2011	73
21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
22898678	1956	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	56
23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
25589610	1956	Schanstra JP	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.	Journal of the American Society of Nephrology 	2015	21
26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
26229137	1956	Stubbs JR	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.	Journal of the American Society of Nephrology 	2016	27
26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	25
26890676	1956	Veitch AM	Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines.	Endoscopy	2016	12
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
27383068	1956	Hill NR	Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.	PloS one	2016	21
17601538	2006	O'Rourke MF	Mechanical factors in arterial aging: a clinical perspective.	Journal of the American College of Cardiology	2007	149
21994960	2006	Spencer M	Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance.	The Journal of clinical endocrinology and metabolism	2011	48
22729285	2006	Wu W	Fast-degrading elastomer enables rapid remodeling of a cell-free synthetic graft into a neoartery.	Nature medicine	2012	53
23536538	2006	Tsamis A	Elastin and collagen fibre microstructure of the human aorta in ageing and disease: a review.	Journal of the Royal Society, Interface	2013	31
24365767	2006	Gilpin SE	Perfusion decellularization of human and porcine lungs: bringing the matrix to clinical scale.	The Journal of heart and lung transplantation 	2014	41
26293758	2006	Guzzardi DG	Valve-Related Hemodynamics Mediate Human Bicuspid Aortopathy: Insights From Wall Shear Stress Mapping.	Journal of the American College of Cardiology	2015	23
12663857	2056	Calvillo L	Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling.	Proceedings of the National Academy of Sciences of the United States of America	2003	85
14525788	2056	Bahlmann FH	Erythropoietin regulates endothelial progenitor cells.	Blood	2004	76
16246965	2056	Ryan S	Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome.	Circulation	2005	144
17108342	2056	Dr√ºeke TB	Normalization of hemoglobin level in patients with chronic kidney disease and anemia.	The New England journal of medicine	2006	290
17276778	2056	Phrommintikul A	Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.	Lancet	2007	80
17462454	2056	Society of Thoracic Surgeons Blood Conservation Guideline Task Force.	Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.	The Annals of thoracic surgery	2007	114
17541822	2056	Hausenloy DJ	Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection.	Heart failure reviews	2007	81
17576662	2056	Westenbrink BD	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.	European heart journal	2007	56
18324962	2056	Arcasoy MO	The non-haematopoietic biological effects of erythropoietin.	British journal of haematology	2008	78
18466917	2056	Robey TE	Systems approaches to preventing transplanted cell death in cardiac repair.	Journal of molecular and cellular cardiology	2008	106
21558517	2056	Najjar SS	Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.	JAMA	2011	53
21900080	2056	Sachdev V	Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.	Circulation	2011	36
23695894	2056	Tefferi A	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.	American journal of hematology	2013	29
25535770	2056	Salvagno GL	Red blood cell distribution width: A simple parameter with multiple clinical applications.	Critical reviews in clinical laboratory sciences	2015	34
25611051	2056	Tefferi A	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.	American journal of hematology	2015	22
26656456	2056	Maxwell PH	HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.	Nature reviews. Nephrology	2016	18
20034863	2078	Braam SR	Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.	Stem cell research	2010	90
21300721	2078	Mirams GR	Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.	Cardiovascular research	2011	51
22028871	2078	Schaaf S	Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology.	PloS one	2011	77
22052944	2078	Lahti AL	Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.	Disease models and mechanisms	2012	86
23690542	2078	Harris K	Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.	Toxicological sciences 	2013	29
24030418	2078	Navarrete EG	Screening drug-induced arrhythmia corrected using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.	Circulation	2013	52
25540418	2078	Morita R	ETS transcription factor ETV2 directly converts human fibroblasts into functional endothelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
26170255	2078	Fermini B	A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.	Journal of biomolecular screening	2016	21
26785135	2078	Eng G	Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes.	Nature communications	2016	14
2889967	2147	Radomski MW	Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.	Lancet	1987	170
9087410	2147	Ishihara H	Protease-activated receptor 3 is a second thrombin receptor in humans.	Nature	1997	143
9348075	2147	Maruyama T	2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release.	Journal of biochemistry	1997	206
11341498	2147	Berckmans RJ	Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.	Thrombosis and haemostasis	2001	94
12588269	2147	Lincoff AM	Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.	JAMA	2003	91
14709404	2147	Birukova AA	Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction.	Microvascular research	2004	86
16257999	2147	Birukova AA	GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction.	American journal of physiology. Lung cellular and molecular physiology	2006	66
17124018	2147	Stone GW	Bivalirudin for patients with acute coronary syndromes.	The New England journal of medicine	2006	110
17306706	2147	Leroyer AS	Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques.	Journal of the American College of Cardiology	2007	66
18499566	2147	Stone GW	Bivalirudin during primary PCI in acute myocardial infarction.	The New England journal of medicine	2008	140
19220204	2147	Vanhoutte PM	Endothelial dysfunction and vascular disease.	Acta physiologica	2009	122
22077816	2147	Tricoci P	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.	The New England journal of medicine	2012	84
22443427	2147	Morrow DA	Vorapaxar in the secondary prevention of atherothrombotic events.	The New England journal of medicine	2012	90
23562920	2147	Larsen TB	Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.	Journal of the American College of Cardiology	2013	59
24226379	2147	De Caterina R	Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.	Thrombosis and haemostasis	2013	28
25660055	2147	Stakos DA	Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction.	European heart journal	2015	23
12805058	2152	Shet AS	Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.	Blood	2003	125
16461845	2152	Steffel J	Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.	Circulation	2006	80
17325255	2152	L√ºscher TF	Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.	Circulation	2007	95
22390643	2152	Tuttolomondo A	Atherosclerosis as an inflammatory disease.	Current pharmaceutical design	2012	44
24864123	2152	Sandler NG	Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.	The Journal of infectious diseases	2014	24
25647528	2152	Zidar DA	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.	Journal of acquired immune deficiency syndromes	2015	25
19470889	2159	APPRAISE Steering Committee and Investigators.	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.	Circulation	2009	46
20934556	2159	Ruff CT	Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).	American heart journal	2010	54
21873708	2159	Fox KA	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.	European heart journal	2011	62
22433576	2159	Skanes AC	Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.	The Canadian journal of cardiology	2012	77
23216615	2159	Agnelli G	Apixaban for extended treatment of venous thromboembolism.	The New England journal of medicine	2013	102
23451769	2159	Frost C	Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.	British journal of clinical pharmacology	2013	38
23784266	2159	Mendell J	Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.	American journal of cardiovascular drugs 	2013	30
23808982	2159	Agnelli G	Oral apixaban for the treatment of acute venous thromboembolism.	The New England journal of medicine	2013	153
24211508	2159	Flaker G	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).	Journal of the American College of Cardiology	2014	22
24251359	2159	Giugliano RP	Edoxaban versus warfarin in patients with atrial fibrillation.	The New England journal of medicine	2013	291
24552831	2159	Sherwood MW	Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).	Circulation	2014	23
26330425	2159	Camm AJ	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.	European heart journal	2016	25
15254584	2200	Judge DP	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome.	The Journal of clinical investigation	2004	85
17701892	2200	Faivre L	Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study.	American journal of human genetics	2007	76
20591885	2200	Loeys BL	The revised Ghent nosology for the Marfan syndrome.	Journal of medical genetics	2010	169
21909107	2200	LeMaire SA	Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1.	Nature genetics	2011	37
7807658	2244	-	Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.	JAMA	1995	131
8035924	2244	Breteler MM	Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.	Neurology	1994	133
8353913	2244	Newman AB	Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group.	Circulation	1993	156
9439492	2244	Ridker PM	Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.	Lancet	1998	137
10187889	2244	Ebrahim S	Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study.	Stroke	1999	100
10591709	2244	Rimm EB	Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors.	BMJ	1999	164
10657556	2244	Yudkin JS	Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?	Atherosclerosis	2000	214
10862640	2244	Gu√©rin AP	Arterial stiffening and vascular calcifications in end-stage renal disease.	Nephrology, dialysis, transplantation 	2000	95
15041083	2244	Steptoe A	Loneliness and neuroendocrine, cardiovascular, and inflammatory stress responses in middle-aged men and women.	Psychoneuroendocrinology	2004	85
15840727	2244	Steptoe A	Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2005	109
16723443	2244	Wong TY	Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA).	Investigative ophthalmology and visual science	2006	92
17463411	2244	Chuang KJ	The effect of urban air pollution on inflammation, oxidative stress, coagulation, and autonomic dysfunction in young adults.	American journal of respiratory and critical care medicine	2007	139
17485598	2244	Roman MJ	Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study.	Hypertension	2007	132
17846344	2244	Kloner RA	To drink or not to drink? That is the question.	Circulation	2007	58
18328671	2244	Suarez EC	Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity.	Brain, behavior, and immunity	2008	64
19672412	2244	Hoffmann B	Chronic residential exposure to particulate matter air pollution and systemic inflammatory markers.	Environmental health perspectives	2009	46
20439481	2244	Thompson S	Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies.	International journal of epidemiology	2010	41
20943795	2244	Mozaffarian D	Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes.	The American journal of clinical nutrition	2010	43
21970887	2244	G√∂rlinger K	First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.	Anesthesiology	2011	43
22253320	2244	McGuinness D	Socio-economic status is associated with epigenetic differences in the pSoBid cohort.	International journal of epidemiology	2012	33
22347441	2244	Pinto Pereira SM	Sedentary behaviour and biomarkers for cardiovascular disease and diabetes in mid-life: the role of television-viewing and sitting at work.	PloS one	2012	39
22665106	2244	Rich DQ	Association between changes in air pollution levels during the Beijing Olympics and biomarkers of inflammation and thrombosis in healthy young adults.	JAMA	2012	51
23194937	2244	Guo Y	Inflammation in atrial fibrillation.	Journal of the American College of Cardiology	2012	64
23249928	2244	Rahe-Meyer N	Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.	Anesthesiology	2013	31
23755138	2244	Menzaghi C	Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes.	PloS one	2014	21
23791463	2244	Miller J	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.	Respiratory medicine	2013	37
24335500	2244	Cines DB	Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin.	Blood	2014	23
24368514	2244	McInnes IB	Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.	Annals of the rheumatic diseases	2015	32
24691204	2244	Longenecker CT	Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.	AIDS	2014	44
8626565	2247	Whitelock JM	The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.	The Journal of biological chemistry	1996	119
11854116	2247	Simons M	Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.	Circulation	2002	96
18220619	2247	Sim√≥ R	Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.	Current diabetes reviews	2006	75
18232728	2247	Pietras K	Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.	PLoS medicine	2008	105
19038683	2247	Takehara N	Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction.	Journal of the American College of Cardiology	2008	52
19197140	2247	Izikki M	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.	The Journal of clinical investigation	2009	49
20643952	2247	Evseenko D	Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
21494607	2247	Burridge PW	A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.	PloS one	2011	120
22188562	2247	Hsiao ST	Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue.	Stem cells and development	2012	58
23863927	2247	Katoh M	Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).	International journal of molecular medicine	2013	27
24481949	2247	Ricard N	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.	Circulation	2014	23
24960162	2247	Bertero T	Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.	The Journal of clinical investigation	2014	43
7929268	2321	Park JE	Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.	The Journal of biological chemistry	1994	149
8605350	2321	Barleon B	Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.	Blood	1996	207
11734454	2321	Bhatt AJ	Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia.	American journal of respiratory and critical care medicine	2001	115
19900040	2321	Kusanovic JP	A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.	The journal of maternal-fetal and neonatal medicine 	2009	67
2445780	2335	Nathan CF	Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes.	The Journal of clinical investigation	1987	164
2589440	2335	Roberts JM	Preeclampsia: an endothelial cell disorder.	American journal of obstetrics and gynecology	1989	178
8335696	2335	DiMilla PA	Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength.	The Journal of cell biology	1993	143
10051240	2335	Salvi S	Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers.	American journal of respiratory and critical care medicine	1999	168
10353737	2335	Brown LF	Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.	Clinical cancer research 	1999	96
10751360	2335	Kim S	Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin.	The American journal of pathology	2000	135
12451003	2335	Tepper OM	Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures.	Circulation	2002	300
15020515	2335	Boldt A	Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease.	Heart	2004	75
22293174	2335	Salmon H	Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.	The Journal of clinical investigation	2012	37
23261219	2335	Rao C	The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells.	Biomaterials	2013	30
24615475	2335	Rodriguez ML	Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts.	Journal of biomechanical engineering	2014	26
14981009	2641	Nikolaidis LA	Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.	Circulation	2004	175
15353407	2641	Nystr√∂m T	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.	American journal of physiology. Endocrinology and metabolism	2004	136
17174230	2641	Sokos GG	Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.	Journal of cardiac failure	2006	122
17711996	2641	Basu A	Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.	American journal of physiology. Endocrinology and metabolism	2007	60
20929995	2641	Best JH	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.	Diabetes care	2011	55
23812094	2641	Wadden TA	Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.	International journal of obesity	2013	37
27295427	2641	Marso SP	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.	The New England journal of medicine	2016	130
27633186	2641	Marso SP	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.	The New England journal of medicine	2016	54
10974216	2697	Boyett MR	The sinoatrial node, a heterogeneous pacemaker structure.	Cardiovascular research	2000	104
12742992	2697	Mummery C	Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells.	Circulation	2003	243
15576650	2697	Ai X	Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A.	Circulation research	2005	70
18048761	2697	Ferdinandy P	Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.	Pharmacological reviews	2007	148
18064002	2697	Roell W	Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia.	Nature	2007	122
19786631	2697	Zwi L	Cardiomyocyte differentiation of human induced pluripotent stem cells.	Circulation	2009	107
19959133	2697	Girmatsion Z	Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation.	Heart rhythm	2009	46
20037143	2697	Bai X	Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction.	European heart journal	2010	46
20038810	2697	Smyth JW	Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium.	The Journal of clinical investigation	2010	74
20093630	2697	Glukhov AV	Transmural dispersion of repolarization in failing and nonfailing human ventricle.	Circulation research	2010	89
20606116	2697	Thibodeau IL	Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue.	Circulation	2010	44
21744185	2697	Duan Y	Hybrid gel composed of native heart matrix and collagen induces cardiac differentiation of human embryonic stem cells without supplemental growth factors.	Journal of cardiovascular translational research	2011	35
21819962	2697	M√°rquez-Rosado L	Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues.	Biochimica et biophysica acta	2012	41
23178689	2697	Noorman M	Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathy.	Heart rhythm	2013	32
23461462	2697	Lundy SD	Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells.	Stem cells and development	2013	129
24852842	2697	Hirt MN	Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation.	Journal of molecular and cellular cardiology	2014	41
25654582	2697	Beauchamp P	Development and Characterization of a Scaffold-Free 3D Spheroid Model of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes.	Tissue engineering. Part C, Methods	2015	18
26291556	2697	Riegler J	Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model.	Circulation research	2015	27
26516000	2697	Nademanee K	Fibrosis, Connexin-43, and Conduction Abnormalities in the Brugada Syndrome.	Journal of the American College of Cardiology	2015	19
9537338	3156	Laufs U	Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.	Circulation	1998	216
11030795	3156	Wolozin B	Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.	Archives of neurology	2000	231
12132975	3156	Benner JS	Long-term persistence in use of statin therapy in elderly patients.	JAMA	2002	219
12672737	3156	Thompson PD	Statin-associated myopathy.	JAMA	2003	174
15199031	3156	Chasman DI	Pharmacogenetic study of statin therapy and cholesterol reduction.	JAMA	2004	86
17640385	3156	Wolozin B	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.	BMC medicine	2007	64
9622162	3162	De Keulenaer GW	Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase.	Circulation research	1998	117
12130498	3162	Jeney V	Pro-oxidant and cytotoxic effects of circulating heme.	Blood	2002	116
15451051	3162	Exner M	The role of heme oxygenase-1 promoter polymorphisms in human disease.	Free radical biology and medicine	2004	89
16408059	3162	Bryan NS	Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues.	Nature chemical biology	2005	111
17413033	3162	Kr√∂nke G	Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.	Arteriosclerosis, thrombosis, and vascular biology	2007	58
19937043	3162	Schrag M	Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study.	Acta neuropathologica	2010	54
21992109	3162	Grochot-Przeczek A	Haem oxygenase-1: non-canonical roles in physiology and pathology.	Clinical science	2012	43
22879597	3162	Cai C	The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release.	The Journal of biological chemistry	2012	39
1361507	3383	Ades EW	HMEC-1: establishment of an immortalized human microvascular endothelial cell line.	The Journal of investigative dermatology	1992	283
2566624	3383	Smith CW	Cooperative interactions of LFA-1 and Mac-1 with intercellular adhesion molecule-1 in facilitating adherence and transendothelial migration of human neutrophils in vitro.	The Journal of clinical investigation	1989	203
7542286	3383	De Caterina R	Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.	The Journal of clinical investigation	1995	226
8476577	3383	Bevilacqua MP	Endothelial-leukocyte adhesion molecules.	Annual review of immunology	1993	186
9347951	3383	Newbold C	Receptor-specific adhesion and clinical disease in Plasmodium falciparum.	The American journal of tropical medicine and hygiene	1997	117
10393703	3383	Combes V	In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.	The Journal of clinical investigation	1999	124
10433933	3383	Silamut K	A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain.	The American journal of pathology	1999	125
10545519	3383	Peled A	The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow.	The Journal of clinical investigation	1999	113
11108718	3383	Kim I	Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.	The Journal of biological chemistry	2001	142
11566912	3383	Chae CU	Blood pressure and inflammation in apparently healthy men.	Hypertension	2001	102
11854119	3383	Ziccardi P	Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.	Circulation	2002	131
11923038	3383	Nappo F	Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.	Journal of the American College of Cardiology	2002	90
15021878	3383	Schenkel AR	Locomotion of monocytes on endothelium is a critical step during extravasation.	Nature immunology	2004	103
15113816	3383	Meigs JB	Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus.	JAMA	2004	128
15811956	3383	Yang L	ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.	Blood	2005	150
16935624	3383	Huang J	Inflammation in stroke and focal cerebral ischemia.	Surgical neurology	2006	133
16973825	3383	Csiszar A	Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition.	American journal of physiology. Heart and circulatory physiology	2006	88
17182639	3383	O'Neill MS	Air pollution and inflammation in type 2 diabetes: a mechanism for susceptibility.	Occupational and environmental medicine	2007	77
19307690	3383	Lawson C	ICAM-1 signaling in endothelial cells.	Pharmacological reports 	2009	133
19910332	3383	Sauvet F	Effect of acute sleep deprivation on vascular function in healthy subjects.	Journal of applied physiology	2010	43
21164106	3383	Rautou PE	Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration.	Circulation research	2011	40
21448265	3383	Meijer K	Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages.	PloS one	2011	52
21852557	3383	Rautou PE	Microparticles, vascular function, and atherothrombosis.	Circulation research	2011	63
26152369	3383	O'Carroll SJ	Pro-inflammatory TNFŒ± and IL-1Œ≤ differentially regulate the inflammatory phenotype of brain microvascular endothelial cells.	Journal of neuroinflammation	2015	20
3877078	3552	Bevilacqua MP	Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines.	The Journal of clinical investigation	1985	204
8496693	3552	Taub DD	Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells.	The Journal of experimental medicine	1993	178
11844745	3552	Pfeilschifter J	Changes in proinflammatory cytokine activity after menopause.	Endocrine reviews	2002	143
12480795	3552	Simopoulos AP	Omega-3 fatty acids in inflammation and autoimmune diseases.	Journal of the American College of Nutrition	2002	188
19110321	3552	Aggarwal BB	Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets.	Trends in pharmacological sciences	2009	145
19479203	3552	Bujak M	The role of IL-1 in the pathogenesis of heart disease.	Archivum immunologiae et therapiae experimentalis	2009	47
20081871	3552	Sims JE	The IL-1 family: regulators of immunity.	Nature reviews. Immunology	2010	231
22945591	3552	Rock KL	Uric acid as a danger signal in gout and its comorbidities.	Nature reviews. Rheumatology	2013	38
23995233	3552	Freigang S	Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1Œ± and sterile vascular inflammation in atherosclerosis.	Nature immunology	2013	46
24321195	3552	Shinde AV	Fibroblasts in myocardial infarction: a role in inflammation and repair.	Journal of molecular and cellular cardiology	2014	60
25726324	3552	Interleukin 1 Genetics Consortium.	Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.	The lancet. Diabetes and endocrinology	2015	15
26209330	3552	Cavalli G	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.	Rheumatology	2015	23
26837745	3552	Ridker PM	From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.	Circulation research	2016	23
27340270	3552	Prabhu SD	The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.	Circulation research	2016	31
8910831	3553	Beck J	Periodontal disease and cardiovascular disease.	Journal of periodontology	1996	179
10430608	3553	Frantz S	Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium.	The Journal of clinical investigation	1999	106
11489912	3553	Lindemann S	Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis.	The Journal of cell biology	2001	97
14581396	3553	Mazurek T	Human epicardial adipose tissue is a source of inflammatory mediators.	Circulation	2003	266
15240608	3553	Malkin CJ	The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.	The Journal of clinical endocrinology and metabolism	2004	96
17475444	3553	Steptoe A	The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis.	Brain, behavior, and immunity	2007	228
19692116	3553	Richette P	Gout.	Lancet	2010	95
20588114	3553	Dinarello CA	Role of IL-1beta in type 2 diabetes.	Current opinion in endocrinology, diabetes, and obesity	2010	74
21159789	3553	Skulas-Ray AC	Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia.	The American journal of clinical nutrition	2011	51
21297467	3553	Boden G	Obesity, insulin resistance and free fatty acids.	Current opinion in endocrinology, diabetes, and obesity	2011	127
21599903	3553	Brochu ME	Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study.	Journal of neuroinflammation	2011	36
21945322	3553	Rieder F	Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis.	The American journal of pathology	2011	60
22101528	3553	Poole DC	Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance.	American journal of physiology. Heart and circulatory physiology	2012	60
22219513	3553	Csiszar A	Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment.	The journals of gerontology. Series A, Biological sciences and medical sciences	2012	39
22829270	3553	Librizzi L	Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.	Annals of neurology	2012	37
23360282	3553	Gola H	Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells.	BMC psychiatry	2013	33
24446952	3553	Rojas A	Cyclooxygenase-2 in epilepsy.	Epilepsia	2014	21
24920309	3553	Jansson D	A role for human brain pericytes in neuroinflammation.	Journal of neuroinflammation	2014	20
26926996	3553	Shirai T	The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease.	The Journal of experimental medicine	2016	16
27270401	3553	Park YH	Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.	Nature immunology	2016	15
9389420	3569	Pickup JC	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.	Diabetologia	1997	150
9398739	3569	Mohamed-Ali V	Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.	The Journal of clinical endocrinology and metabolism	1997	276
10720054	3569	Vgontzas AN	Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.	The Journal of clinical endocrinology and metabolism	2000	180
11388092	3569	Pinede L	Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases.	Medicine	2001	92
12551862	3569	Devaraj S	C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.	Circulation	2003	77
12637131	3569	Cohen HJ	Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly.	The American journal of medicine	2003	78
12840146	3569	Kiecolt-Glaser JK	Chronic stress and age-related increases in the proinflammatory cytokine IL-6.	Proceedings of the National Academy of Sciences of the United States of America	2003	248
15705924	3569	Alesci S	Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications.	The Journal of clinical endocrinology and metabolism	2005	67
15780075	3569	Stenvinkel P	IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly.	Kidney international	2005	107
15893251	3569	Vgontzas AN	Sleep apnea is a manifestation of the metabolic syndrome.	Sleep medicine reviews	2005	68
16120716	3569	Minoguchi K	Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea.	American journal of respiratory and critical care medicine	2005	85
16227461	3569	Punjabi NM	Disorders of glucose metabolism in sleep apnea.	Journal of applied physiology	2005	84
16412224	3569	Baker AR	Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease.	Cardiovascular diabetology	2006	121
16584505	3569	Ronti T	The endocrine function of adipose tissue: an update.	Clinical endocrinology	2006	115
16613757	3569	Bastard JP	Recent advances in the relationship between obesity, inflammation, and insulin resistance.	European cytokine network	2006	383
16737350	3569	Yang RZ	Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.	PLoS medicine	2006	69
17446340	3569	T√∂rnqvist H	Persistent endothelial dysfunction in humans after diesel exhaust inhalation.	American journal of respiratory and critical care medicine	2007	94
17654441	3569	Hartge MM	The endothelium and vascular inflammation in diabetes.	Diabetes and vascular disease research	2007	55
17716366	3569	Jeschke MG	Burn size determines the inflammatory and hypermetabolic response.	Critical care	2007	58
18220642	3569	Hamdy O	Metabolic obesity: the paradox between visceral and subcutaneous fat.	Current diabetes reviews	2006	96
18369199	3569	Yende S	Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.	American journal of respiratory and critical care medicine	2008	70
18753925	3569	Strategies for Management of Anti-Retroviral Therapy/INSIGHT.	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.	AIDS	2008	81
18926166	3569	Libby P	Role of inflammation in atherosclerosis associated with rheumatoid arthritis.	The American journal of medicine	2008	54
18926322	3569	Martin SS	Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease.	Journal of the American College of Cardiology	2008	92
19122178	3569	Chatterjee TK	Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding.	Circulation research	2009	112
19268915	3569	Lindqvist D	Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.	Biological psychiatry	2009	93
19289637	3569	Greenstein AS	Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients.	Circulation	2009	113
19318968	3569	Tarantino G	Could inflammatory markers help diagnose nonalcoholic steatohepatitis?	European journal of gastroenterology and hepatology	2009	46
19497986	3569	Lehrke M	Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis.	European journal of endocrinology	2009	48
19639748	3569	Miller MA	Gender differences in the cross-sectional relationships between sleep duration and markers of inflammation: Whitehall II study.	Sleep	2009	63
19781428	3569	F√∂rh√©cz Z	Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state.	American heart journal	2009	76
19794059	3569	Mehta NN	Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.	Diabetes	2010	82
19828697	3569	Funderburg NT	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.	Blood	2010	89
20660122	3569	Roberts ET	Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up.	American journal of epidemiology	2010	81
20679216	3569	Slavich GM	Neural sensitivity to social rejection is associated with inflammatory responses to social stress.	Proceedings of the National Academy of Sciences of the United States of America	2010	78
22022504	3569	Lee N	Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults.	PloS one	2011	41
22146091	3569	Pervanidou P	Metabolic consequences of stress during childhood and adolescence.	Metabolism	2012	45
22421340	3569	Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.	Lancet	2012	130
22687336	3569	Hiles SA	A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity.	Brain, behavior, and immunity	2012	35
22743373	3569	Ostrowski SR	Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy.	The journal of trauma and acute care surgery	2012	36
22970224	3569	Duprez DA	Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.	PloS one	2012	150
23034965	3569	Itariu BK	Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial.	The American journal of clinical nutrition	2012	38
23065151	3569	Funderburg NT	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome.	Blood	2012	73
23332012	3569	Longenecker CT	Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals.	HIV medicine	2013	52
23340215	3569	Singh AK	Metabolic syndrome and chronic kidney disease.	Current opinion in nephrology and hypertension	2013	27
23392440	3569	Vanfleteren LE	Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2013	88
24033321	3569	Patel AR	Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2013	30
24728071	3569	Miller CJ	Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.	PloS one	2014	22
24870935	3569	Nordell AD	Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.	Journal of the American Heart Association	2014	34
25069991	3569	Harman SM	Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.	Annals of internal medicine	2014	38
26347573	3569	Siedner MJ	Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy.	The Journal of infectious diseases	2016	12
26781070	3569	Domingueti CP	Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.	Journal of diabetes and its complications	2016	18
26858430	3569	Morris CJ	Circadian misalignment increases cardiovascular disease risk factors in humans.	Proceedings of the National Academy of Sciences of the United States of America	2016	16
1671422	3630	McKeigue PM	Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians.	Lancet	1991	260
2044434	3630	DeFronzo RA	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.	Diabetes care	1991	373
7839388	3630	Sacco RL	Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.	Stroke	1995	138
8622248	3630	Kannel WB	Blood pressure as a cardiovascular risk factor: prevention and treatment.	JAMA	1996	133
9303923	3630	Ferrannini E	Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR).	The Journal of clinical investigation	1997	116
9673301	3630	Haffner SM	Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.	The New England journal of medicine	1998	841
9920074	3630	Banerji MA	Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men.	The Journal of clinical endocrinology and metabolism	1999	100
10189543	3630	-	The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.	Diabetes care	1999	180
10209084	3630	Andrews RC	Glucocorticoids and insulin resistance: old hormones, new targets.	Clinical science	1999	100
10512371	3630	Moran A	Insulin resistance during puberty: results from clamp studies in 357 children.	Diabetes	1999	131
10896648	3630	Ross R	Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial.	Annals of internal medicine	2000	199
10902785	3630	Katz A	Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.	The Journal of clinical endocrinology and metabolism	2000	472
11124751	3630	Fung TT	Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk.	The American journal of clinical nutrition	2001	121
11274526	3630	Visscher TL	The public health impact of obesity.	Annual review of public health	2001	128
11587045	3630	Morrish NJ	Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.	Diabetologia	2001	167
12081851	3630	Willett W	Glycemic index, glycemic load, and risk of type 2 diabetes.	The American journal of clinical nutrition	2002	81
12087016	3630	Hanley AJ	Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.	Diabetes care	2002	96
12364302	3630	DAFNE Study Group.	Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial.	BMJ	2002	123
12540621	3630	Garvey WT	Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.	Diabetes	2003	93
12551870	3630	Rutter MK	Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study.	Circulation	2003	97
12642369	3630	Steinberger J	Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism).	Circulation	2003	121
12679416	3630	Goran MI	Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents.	The Journal of clinical endocrinology and metabolism	2003	100
12788835	3630	Carr MC	The emergence of the metabolic syndrome with menopause.	The Journal of clinical endocrinology and metabolism	2003	202
14623617	3630	McLaughlin T	Use of metabolic markers to identify overweight individuals who are insulin resistant.	Annals of internal medicine	2003	151
14715836	3630	Cruz ML	The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity.	The Journal of clinical endocrinology and metabolism	2004	100
15123530	3630	Peterson LR	Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women.	Circulation	2004	122
15623819	3630	Apridonidze T	Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.	The Journal of clinical endocrinology and metabolism	2005	88
15655131	3630	Antzelevitch C	Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.	Circulation	2005	210
15669880	3630	Krentz AJ	Oral antidiabetic agents: current role in type 2 diabetes mellitus.	Drugs	2005	126
15851602	3630	Gardner JP	Rise in insulin resistance is associated with escalated telomere attrition.	Circulation	2005	98
15883415	3630	Nair KS	Aging muscle.	The American journal of clinical nutrition	2005	82
16061606	3630	Hannon TS	Childhood obesity and type 2 diabetes mellitus.	Pediatrics	2005	67
16061755	3630	Dekker JM	Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.	Circulation	2005	91
16103522	3630	Bassuk SS	Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease.	Journal of applied physiology	2005	88
16388523	3630	Basaria S	Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.	Cancer	2006	65
16434464	3630	Smith MR	Insulin sensitivity during combined androgen blockade for prostate cancer.	The Journal of clinical endocrinology and metabolism	2006	98
16532897	3630	Serra-Majem L	Scientific evidence of interventions using the Mediterranean diet: a systematic review.	Nutrition reviews	2006	73
16567536	3630	Festa A	The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study.	Diabetes	2006	73
16644702	3630	Clerk LH	Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.	Diabetes	2006	80
16801565	3630	Knopp RH	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).	Diabetes care	2006	69
16813742	3630	Ness RB	Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia.	American journal of obstetrics and gynecology	2006	79
16860699	3630	Andersen LB	Physical activity and clustered cardiovascular risk in children: a cross-sectional study (The European Youth Heart Study).	Lancet	2006	225
17021763	3630	Sommer DM	Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.	Archives of dermatological research	2006	84
17145742	3630	Kahn SE	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.	The New England journal of medicine	2006	516
17339025	3630	Holland WL	Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.	Cell metabolism	2007	313
17443605	3630	Horvath K	Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.	The Cochrane database of systematic reviews	2007	62
17707755	3630	Messerli FH	Essential hypertension.	Lancet	2007	76
17957034	3630	Muniyappa R	Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.	American journal of physiology. Endocrinology and metabolism	2008	261
18191731	3630	Witteles RM	Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options.	Journal of the American College of Cardiology	2008	74
18197184	3630	Trapp EG	The effects of high-intensity intermittent exercise training on fat loss and fasting insulin levels of young women.	International journal of obesity	2008	57
18250214	3630	Tasali E	Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation.	Proceedings of the American Thoracic Society	2008	75
18319352	3630	Dub√© JJ	Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited.	American journal of physiology. Endocrinology and metabolism	2008	94
18434349	3630	Macfarlane DP	Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome.	The Journal of endocrinology	2008	64
18463376	3630	Rowan JA	Metformin versus insulin for the treatment of gestational diabetes.	The New England journal of medicine	2008	103
18469239	3630	Stanhope KL	Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals.	The American journal of clinical nutrition	2008	58
18544448	3630	Shaw JE	Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention.	Diabetes research and clinical practice	2008	58
18673007	3630	King GL	The role of inflammatory cytokines in diabetes and its complications.	Journal of periodontology	2008	90
18987276	3630	Misra A	Obesity and the metabolic syndrome in developing countries.	The Journal of clinical endocrinology and metabolism	2008	182
19141606	3630	Maratou E	Studies of insulin resistance in patients with clinical and subclinical hypothyroidism.	European journal of endocrinology	2009	49
19211823	3630	Nicklas BJ	Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women: a randomized, controlled trial.	The American journal of clinical nutrition	2009	53
19246357	3630	Sacks FM	Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates.	The New England journal of medicine	2009	293
19281826	3630	Roberts CK	Oxidative stress and metabolic syndrome.	Life sciences	2009	108
19358089	3630	Bl√ºher M	Adipose tissue dysfunction in obesity.	Experimental and clinical endocrinology and diabetes 	2009	101
19407331	3630	Huang PL	A comprehensive definition for metabolic syndrome.	Disease models and mechanisms	2009	93
19588120	3630	Jonasson JM	Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.	Diabetologia	2009	97
19712802	3630	Caminiti G	Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study.	Journal of the American College of Cardiology	2009	56
19789205	3630	Kalyani RR	The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women.	The Journal of clinical endocrinology and metabolism	2009	51
19859074	3630	Zitzmann M	Testosterone deficiency, insulin resistance and the metabolic syndrome.	Nature reviews. Endocrinology	2009	46
19915016	3630	Nadeau KJ	Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.	The Journal of clinical endocrinology and metabolism	2010	71
20086073	3630	Tappy L	Metabolic effects of fructose and the worldwide increase in obesity.	Physiological reviews	2010	188
20103556	3630	Peyrot M	Correlates of insulin injection omission.	Diabetes care	2010	77
20220183	3630	Patel MR	Low diagnostic yield of elective coronary angiography.	The New England journal of medicine	2010	132
20228402	3630	NAVIGATOR Study Group.	Effect of nateglinide on the incidence of diabetes and cardiovascular events.	The New England journal of medicine	2010	73
20339361	3630	Preis SR	Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study.	Obesity	2010	80
20361178	3630	DeFronzo RA	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.	Diabetologia	2010	131
20370677	3630	Bugianesi E	Insulin resistance in nonalcoholic fatty liver disease.	Current pharmaceutical design	2010	50
20376052	3630	Hotamisligil GS	Endoplasmic reticulum stress and atherosclerosis.	Nature medicine	2010	70
20457594	3630	Catalano PM	Obesity, insulin resistance, and pregnancy outcome.	Reproduction	2010	50
20484490	3630	Preis SR	Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study.	The Journal of clinical endocrinology and metabolism	2010	62
20802107	3630	Burt Solorzano CM	Obesity and the pubertal transition in girls and boys.	Reproduction	2010	52
20978091	3630	Schauer IE	Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study.	Diabetes	2011	48
21050286	3630	Caesar R	Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism.	Journal of internal medicine	2010	42
21051417	3630	Yu Q	Insulin says NO to cardiovascular disease.	Cardiovascular research	2011	36
21109513	3630	Kitas GD	Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives.	Annals of the rheumatic diseases	2011	50
21109577	3630	Lawlor DA	Association between general and central adiposity in childhood, and change in these, with cardiovascular risk factors in adolescence: prospective cohort study.	BMJ	2010	73
21216854	3630	Schmid AI	Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.	Diabetes care	2011	36
21298090	3630	Lee DH	Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes.	PloS one	2011	78
21471135	3630	Schramm TK	Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.	European heart journal	2011	63
21718726	3630	Dongiovanni P	Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.	Journal of hepatology	2011	59
21762726	3630	Poudyal H	Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action.	Progress in lipid research	2011	42
22326434	3630	Cusi K	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.	Gastroenterology	2012	112
22332072	3630	Kalupahana NS	(n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights.	Advances in nutrition	2011	49
22344039	3630	Fraser A	Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children.	Circulation	2012	52
22592687	3630	Tang T	Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.	The Cochrane database of systematic reviews	2012	47
22722431	3630	Miliƒá S	Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.	Digestive diseases	2012	47
22741595	3630	Liu CJ	Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese.	Journal of gastroenterology and hepatology	2012	34
22876189	3630	Voight BF	The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits.	PLoS genetics	2012	190
23015032	3630	Friedemann C	Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis.	BMJ	2012	58
23129134	3630	W√ºrtz P	Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults.	Diabetes care	2013	65
23164767	3630	Jacobi J	Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients.	Critical care medicine	2012	64
23356701	3630	Weiss R	What is metabolic syndrome, and why are children getting it?	Annals of the New York Academy of Sciences	2013	42
23363012	3630	Masuoka HC	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.	Annals of the New York Academy of Sciences	2013	44
23370525	3630	Goldfine AB	A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance.	Diabetologia	2013	31
23458891	3630	Farrell GC	NAFLD in Asia--as common and important as in the West.	Nature reviews. Gastroenterology and hepatology	2013	69
23863634	3630	Ruderman NB	AMPK, insulin resistance, and the metabolic syndrome.	The Journal of clinical investigation	2013	120
23863826	3630	Misra A	Obesity and dyslipidemia in South Asians.	Nutrients	2013	32
23877060	3630	Cahill LE	Prospective study of breakfast eating and incident coronary heart disease in a cohort of male US health professionals.	Circulation	2013	29
23929732	3630	Birkenfeld AL	Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.	Hepatology	2014	70
23938049	3630	Bahadoran Z	Dietary polyphenols as potential nutraceuticals in management of diabetes: a review.	Journal of diabetes and metabolic disorders	2013	34
24250251	3630	Rajendran P	The vascular endothelium and human diseases.	International journal of biological sciences	2013	62
24429158	3630	Aurora RN	Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association.	The Lancet. Respiratory medicine	2013	28
24458353	3630	Leproult R	Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss.	Diabetes	2014	68
24529130	3630	Alexopoulos N	Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis.	Atherosclerosis	2014	31
24663222	3630	Laakso M	Insulin resistance and hyperglycaemia in cardiovascular disease development.	Nature reviews. Endocrinology	2014	31
24757202	3630	Chow E	Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.	Diabetes	2014	33
24928681	3630	Montaigne D	Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients.	Circulation	2014	28
25035342	3630	Lim S	Links between ectopic fat and vascular disease in humans.	Arteriosclerosis, thrombosis, and vascular biology	2014	24
25176147	3630	Khan MT	Microbial modulation of insulin sensitivity.	Cell metabolism	2014	22
25261534	3630	Ferdinandy P	Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning.	Pharmacological reviews	2014	64
25287289	3630	Frier BM	Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications.	Nature reviews. Endocrinology	2014	28
25766618	3630	Kim B	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome.	Experimental and molecular medicine	2015	20
25825943	3630	Schwarz JM	Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat.	The Journal of clinical endocrinology and metabolism	2015	20
26319013	3630	Negro F	Extrahepatic morbidity and mortality of chronic hepatitis C.	Gastroenterology	2015	19
26549485	3630	Tian XY	Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance.	Cell metabolism	2016	13
26628415	3630	Henson J	Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study.	Diabetes care	2016	13
26678809	3630	Jia G	Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.	Nature reviews. Endocrinology	2016	25
26863521	3630	Ho JE	Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes.	PloS one	2016	12
26886418	3630	Kernan WN	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.	The New England journal of medicine	2016	45
27409811	3630	Pedersen HK	Human gut microbes impact host serum metabolome and insulin sensitivity.	Nature	2016	31
8587608	3757	Smith PL	The inward rectification mechanism of the HERG cardiac potassium channel.	Nature	1996	194
8740374	3757	Spector PS	Fast inactivation causes rectification of the IKr channel.	The Journal of general physiology	1996	140
18616963	3757	Hancox JC	The hERG potassium channel and hERG screening for drug-induced torsades de pointes.	Pharmacology and therapeutics	2008	59
21240260	3757	Itzhaki I	Modelling the long QT syndrome with induced pluripotent stem cells.	Nature	2011	277
21367833	3757	Matsa E	Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.	European heart journal	2011	106
22988594	3757	Vandenberg JI	hERG K(+) channels: structure, function, and clinical significance.	Physiological reviews	2012	92
23277474	3757	Terrenoire C	Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.	The Journal of general physiology	2013	52
23470493	3757	Matsa E	Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes.	European heart journal	2014	28
24213244	3757	Bellin M	Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.	The EMBO journal	2013	46
9804796	3791	Gerber HP	Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.	The Journal of biological chemistry	1998	366
9892193	3791	Fong TA	SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.	Cancer research	1999	145
10022831	3791	Soldi R	Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.	The EMBO journal	1999	118
11387210	3791	Takahashi T	A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.	The EMBO journal	2001	170
11440984	3791	Vasa M	Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.	Circulation research	2001	415
11719508	3791	Colavitti R	Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.	The Journal of biological chemistry	2002	82
12620408	3791	Bais C	Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR.	Cancer cell	2003	80
15308462	3791	Asahara T	Endothelial progenitor cells for postnatal vasculogenesis.	American journal of physiology. Cell physiology	2004	93
15862416	3791	Heiss C	Impaired progenitor cell activity in age-related endothelial dysfunction.	Journal of the American College of Cardiology	2005	103
15927972	3791	Schmidt-Lucke C	Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair.	Circulation	2005	201
16148285	3791	Werner N	Circulating endothelial progenitor cells and cardiovascular outcomes.	The New England journal of medicine	2005	389
17569886	3791	Ferreira LS	Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo.	Circulation research	2007	74
17588480	3791	Case J	Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors.	Experimental hematology	2007	132
18063830	3791	Yip HK	Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke.	Stroke	2008	51
18559524	3791	Hilberg F	BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.	Cancer research	2008	123
18977327	3791	W√ºrdinger T	miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.	Cancer cell	2008	120
19007739	3791	Norden AD	Novel anti-angiogenic therapies for malignant gliomas.	The Lancet. Neurology	2008	50
19717420	3791	Bearzi C	Identification of a coronary vascular progenitor cell in the human heart.	Proceedings of the National Academy of Sciences of the United States of America	2009	70
21653826	3791	Herzog B	VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation.	Molecular biology of the cell	2011	50
22718841	3791	Jiang T	CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis.	Blood	2012	36
25240821	3791	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	184
9588554	3827	Kroll RA	Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.	Neurosurgery	1998	111
16365212	3827	Mills NL	Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis.	Circulation	2005	150
17200437	3827	Campbell WB	Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors.	Hypertension	2007	71
19297385	3827	Antoniades C	Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.	European heart journal	2009	53
20224870	3827	Campbell WB	Epoxyeicosatrienoic acids and endothelium-dependent responses.	Pflugers Archiv 	2010	76
25791797	3827	van Tellingen O	Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.	Drug resistance updates 	2015	28
8614836	3949	Geisterfer-Lowrance AA	A mouse model of familial hypertrophic cardiomyopathy.	Science	1996	113
16416046	3949	Tardiff JC	Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.	Heart failure reviews	2005	73
22881376	3949	Usifo E	Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.	Annals of human genetics	2012	41
8684156	3952	Caro JF	Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.	Lancet	1996	126
9815153	3952	Bouloumi√© A	Leptin, the product of Ob gene, promotes angiogenesis.	Circulation research	1998	103
11342529	3952	Yamagishi SI	Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A.	The Journal of biological chemistry	2001	97
11818477	3952	Unger RH	Lipotoxic diseases.	Annual review of medicine	2002	173
18391168	3952	Abel ED	Cardiac remodeling in obesity.	Physiological reviews	2008	131
19584181	3952	Tarcin O	Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects.	The Journal of clinical endocrinology and metabolism	2009	75
23883674	3952	Mark AL	Selective leptin resistance revisited.	American journal of physiology. Regulatory, integrative and comparative physiology	2013	35
15102615	4256	Vattikuti R	Osteogenic regulation of vascular calcification: an early perspective.	American journal of physiology. Endocrinology and metabolism	2004	70
20479029	4256	Parker BD	The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.	Annals of internal medicine	2010	116
22169620	4256	Westenfeld R	Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial.	American journal of kidney diseases 	2012	32
23375872	4256	Schurgers LJ	Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization.	Trends in molecular medicine	2013	28
23349535	4306	Bender SB	Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?	Diabetes	2013	42
24716680	4306	Pitt B	Spironolactone for heart failure with preserved ejection fraction.	The New England journal of medicine	2014	115
8958220	4313	Rajagopalan S	Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.	The Journal of clinical investigation	1996	164
11181465	4313	Crisby M	Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.	Circulation	2001	88
11839588	4313	Taraboletti G	Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.	The American journal of pathology	2002	98
15545316	4313	Chun TH	MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix.	The Journal of cell biology	2004	98
16636176	4313	Ahmed SH	Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.	Circulation	2006	78
18093986	4313	Adya R	Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.	Cardiovascular research	2008	70
21454822	4313	Candelario-Jalil E	Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.	Stroke	2011	37
24281743	4313	Jickling GC	Hemorrhagic transformation after ischemic stroke in animals and humans.	Journal of cerebral blood flow and metabolism 	2014	38
8721615	4353	Berliner JA	The role of oxidized lipoproteins in atherogenesis.	Free radical biology and medicine	1996	122
11694155	4353	Zhang R	Association between myeloperoxidase levels and risk of coronary artery disease.	JAMA	2001	139
12952835	4353	Baldus S	Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.	Circulation	2003	145
22267330	4353	Charles-Schoeman C	Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.	Annals of the rheumatic diseases	2012	34
23818485	4353	Borissoff JI	Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state.	Arteriosclerosis, thrombosis, and vascular biology	2013	36
24291281	4353	Ky B	Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.	Journal of the American College of Cardiology	2014	43
25547404	4353	Mangold A	Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size.	Circulation research	2015	19
15713945	4513	Nussmeier NA	Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.	The New England journal of medicine	2005	120
17087947	4513	Baron JA	A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.	Gastroenterology	2006	101
19336730	4513	Bertagnolli MM	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.	Cancer prevention research	2009	61
19410194	4513	Cuzick J	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.	The Lancet. Oncology	2009	171
20059330	4513	Grosser T	Emotion recollected in tranquility: lessons learned from the COX-2 saga.	Annual review of medicine	2010	58
20388211	4513	McGauran N	Reporting bias in medical research - a narrative review.	Trials	2010	46
21843325	4513	Innala L	Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.	Arthritis research and therapy	2011	38
22310222	4513	Laine L	Management of patients with ulcer bleeding.	The American journal of gastroenterology	2012	71
23726390	4513	Coxib and traditional NSAID Trialists' (CNT) Collaboration.	Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.	Lancet	2013	131
27638428	4513	Kunnumakkara AB	Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases.	British journal of pharmacology	2017	10
12387655	4524	Klerk M	MTHFR 677C--&amp;gt;T polymorphism and risk of coronary heart disease: a meta-analysis.	JAMA	2002	125
15652605	4524	Casas JP	Homocysteine and stroke: evidence on a causal link from mendelian randomisation.	Lancet	2005	75
20446114	4524	Ueland PM	Choline and betaine in health and disease.	Journal of inherited metabolic disease	2011	52
25771069	4524	Huo Y	Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.	JAMA	2015	58
19273718	4607	van Dijk SJ	Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.	Circulation	2009	83
19574547	4607	Marston S	Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency.	Circulation research	2009	50
20850451	4607	Copeland O	Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle.	Journal of molecular and cellular cardiology	2010	47
22178992	4607	van Dijk SJ	Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.	Circulation. Heart failure	2012	34
23281406	4607	McNally EM	Genetic mutations and mechanisms in dilated cardiomyopathy.	The Journal of clinical investigation	2013	75
23396983	4607	Lopes LR	Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing.	Journal of medical genetics	2013	32
23508784	4607	Sequeira V	Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.	Circulation research	2013	52
15047770	4843	Schrage WG	Local inhibition of nitric oxide and prostaglandins independently reduces forearm exercise hyperaemia in humans.	The Journal of physiology	2004	71
15364894	4843	Xu W	Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension.	FASEB journal 	2004	98
15774613	4843	Dejam A	Erythrocytes are the major intravascular storage sites of nitrite in human blood.	Blood	2005	79
25799991	4843	Lee DI	Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.	Nature	2015	24
7540722	4846	Giaid A	Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.	The New England journal of medicine	1995	175
9399960	4846	Papapetropoulos A	Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.	The Journal of clinical investigation	1997	194
9727051	4846	Laufs U	Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.	The Journal of biological chemistry	1998	174
12093770	4846	Takemoto M	Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase.	Circulation	2002	90
12270858	4846	Wallerath T	Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase.	Circulation	2002	94
14605020	4846	Gulati R	Diverse origin and function of cells with endothelial phenotype obtained from adult human blood.	Circulation research	2003	95
15276015	4846	Oudit GY	The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.	Journal of molecular and cellular cardiology	2004	107
16585403	4846	F√∂rstermann U	Endothelial nitric oxide synthase in vascular disease: from marvel to menace.	Circulation	2006	327
17237240	4846	Zhang DX	Mitochondrial reactive oxygen species-mediated signaling in endothelial cells.	American journal of physiology. Heart and circulatory physiology	2007	102
18382884	4846	M√ºnzel T	Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction.	Annals of medicine	2008	76
20159829	4846	Jelic S	Vascular inflammation in obesity and sleep apnea.	Circulation	2010	42
21838680	4846	Folli F	The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach.	Current diabetes reviews	2011	42
22079549	4846	Toda N	Age-related changes in endothelial function and blood flow regulation.	Pharmacology and therapeutics	2012	32
10791374	4879	Troughton RW	Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.	Lancet	2000	128
12225726	4879	Redfield MM	Plasma brain natriuretic peptide concentration: impact of age and gender.	Journal of the American College of Cardiology	2002	105
12892964	4879	de Lemos JA	B-type natriuretic peptide in cardiovascular disease.	Lancet	2003	103
15716560	4879	Kragelund C	N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.	The New England journal of medicine	2005	73
15774989	4879	Doust JA	How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.	BMJ	2005	89
17090767	4879	Bursi F	Systolic and diastolic heart failure in the community.	JAMA	2006	174
18154959	4879	Daniels LB	Natriuretic peptides.	Journal of the American College of Cardiology	2007	127
18598886	4879	Anderson PA	Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study.	Journal of the American College of Cardiology	2008	61
18760965	4879	Maisel A	State of the art: using natriuretic peptide levels in clinical practice.	European journal of heart failure	2008	87
19176440	4879	Pfisterer M	BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.	JAMA	2009	61
19329178	4879	Teerlink JR	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.	Lancet	2009	70
19917883	4879	Di Angelantonio E	B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.	Circulation	2009	69
22634740	4879	Flett AS	Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study.	European heart journal cardiovascular Imaging	2012	35
23040568	4879	Akiyama E	Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.	Journal of the American College of Cardiology	2012	36
23821090	4879	Ledwidge M	Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.	JAMA	2013	39
24275629	4879	Matsuzawa Y	Peripheral endothelial function and cardiovascular events in high-risk patients.	Journal of the American Heart Association	2013	31
25444145	4879	Tang WH	Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis.	Journal of the American College of Cardiology	2014	50
26056125	4879	Chung ES	Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.	European heart journal	2015	17
20385360	4973	Hirsch HA	A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.	Cancer cell	2010	89
21701070	4973	Besler C	Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.	The Journal of clinical investigation	2011	107
27256928	4973	Di Pietro N	Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis.	Vascular pharmacology	2016	14
11071182	5054	Anand SS	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)	Lancet	2000	179
17296677	5054	Cumashi A	A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds.	Glycobiology	2007	98
23224687	5054	Tom√©-Carneiro J	Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease.	Cardiovascular drugs and therapy	2013	28
11917100	5175	Levenberg S	Endothelial cells derived from human embryonic stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	147
11940546	5175	Atkinson C	Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.	Circulation	2002	130
15111498	5175	Curat CA	From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes.	Diabetes	2004	116
15548691	5175	Hida K	Tumor-associated endothelial cells with cytogenetic abnormalities.	Cancer research	2004	97
16773076	5175	Des Guetz G	Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature.	British journal of cancer	2006	78
17446880	5175	Duda DG	A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.	Nature protocols	2007	76
18652940	5175	Joner M	Endothelial cell recovery between comparator polymer-based drug-eluting stents.	Journal of the American College of Cardiology	2008	76
18665180	5175	Beckermann BM	VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.	British journal of cancer	2008	85
19389562	5175	Sluimer JC	Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage.	Journal of the American College of Cardiology	2009	46
19642856	5175	Lesman A	Transplantation of a tissue-engineered human vascularized cardiac muscle.	Tissue engineering. Part A	2010	65
24412187	5175	Beer AJ	PET/CT imaging of integrin Œ±vŒ≤3 expression in human carotid atherosclerosis.	JACC. Cardiovascular imaging	2014	24
24467430	5175	Manetti M	A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis.	Journal of cellular and molecular medicine	2014	24
18349088	5444	Bhattacharyya T	Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.	JAMA	2008	119
11309497	5465	Oliver WR Jr	A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.	Proceedings of the National Academy of Sciences of the United States of America	2001	175
15522914	5465	Sharma S	Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.	FASEB journal 	2004	173
16511589	5465	Lefebvre P	Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.	The Journal of clinical investigation	2006	178
17261671	5465	Brown JD	Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.	Circulation	2007	82
17428730	5465	Rubenstrunk A	Safety issues and prospects for future generations of PPAR modulators.	Biochimica et biophysica acta	2007	68
18510434	5465	Swarbrick MM	Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.	Metabolic syndrome and related disorders	2008	63
19515415	5465	Henry RR	Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.	Lancet	2009	47
25259918	5465	Agudelo LZ	Skeletal muscle PGC-1Œ±1 modulates kynurenine metabolism and mediates resilience to stress-induced depression.	Cell	2014	56
11297596	5741	Pfeifer M	Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.	The Journal of clinical endocrinology and metabolism	2001	112
12081584	5741	Chertow GM	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.	Kidney international	2002	183
15284307	5741	Block GA	Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.	Journal of the American Society of Nephrology 	2004	404
15698460	5741	Young EW	Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study.	Kidney international	2005	115
15814832	5741	Slinin Y	Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.	Journal of the American Society of Nephrology 	2005	76
16316359	5741	Agarwal R	Antiproteinuric effect of oral paricalcitol in chronic kidney disease.	Kidney international	2005	84
16600341	5741	Zittermann A	Vitamin D and disease prevention with special reference to cardiovascular disease.	Progress in biophysics and molecular biology	2006	79
17091124	5741	Levin A	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.	Kidney international	2007	242
18667733	5741	Regidor DL	Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.	Journal of the American Society of Nephrology 	2008	53
19451355	5741	Hagstr√∂m E	Plasma parathyroid hormone and the risk of cardiovascular mortality in the community.	Circulation	2009	82
20861820	5741	Wesseling-Perry K	Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.	Kidney international	2011	47
20947538	5741	Drechsler C	Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study.	Nephrology, dialysis, transplantation 	2011	35
21406649	5741	Palmer SC	Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.	JAMA	2011	121
21939825	5741	Kestenbaum B	Vitamin D, parathyroid hormone, and cardiovascular events among older adults.	Journal of the American College of Cardiology	2011	52
22473330	5741	Thompson B	Arterial calcification and bone physiology: role of the bone-vascular axis.	Nature reviews. Endocrinology	2012	44
23922354	5741	Bouillon R	Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine.	The Journal of clinical endocrinology and metabolism	2013	38
24690624	5741	Theodoratou E	Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials.	BMJ	2014	104
1380156	5743	Hla T	Human cyclooxygenase-2 cDNA.	Proceedings of the National Academy of Sciences of the United States of America	1992	183
8816815	5743	Topper JN	Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress.	Proceedings of the National Academy of Sciences of the United States of America	1996	137
11034610	5743	Serhan CN	Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.	The Journal of experimental medicine	2000	250
11087881	5743	Bombardier C	Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.	The New England journal of medicine	2000	423
11509060	5743	Mukherjee D	Risk of cardiovascular events associated with selective COX-2 inhibitors.	JAMA	2001	195
15582059	5743	J√ºni P	Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.	Lancet	2004	119
15713943	5743	Bresalier RS	Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.	The New England journal of medicine	2005	366
15713944	5743	Solomon SD	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.	The New England journal of medicine	2005	337
15947398	5743	Hippisley-Cox J	Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.	BMJ	2005	86
16943400	5743	Bertagnolli MM	Celecoxib for the prevention of sporadic colorectal adenomas.	The New England journal of medicine	2006	267
16968831	5743	McGettigan P	Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.	JAMA	2006	151
18378608	5743	Solomon SD	Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.	Circulation	2008	89
18413499	5743	Jelic S	Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea.	Circulation	2008	91
20007921	5743	Albini A	Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.	Journal of the National Cancer Institute	2010	89
20083829	5743	Barkun AN	International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding.	Annals of internal medicine	2010	171
23420266	5743	Abdulla A	Guidance on the management of pain in older people.	Age and ageing	2013	61
25322082	5743	K√∂hler O	Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials.	JAMA psychiatry	2014	47
25776112	5743	Solomon DH	Disease activity in rheumatoid arthritis and the risk of cardiovascular events.	Arthritis and rheumatology	2015	17
11230313	5972	Weinberger MH	Salt sensitivity, pulse pressure, and death in normal and hypertensive humans.	Hypertension	2001	113
15837256	5972	Milliez P	Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.	Journal of the American College of Cardiology	2005	138
16157788	5972	Cornelissen VA	Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors.	Hypertension	2005	88
16197570	5972	Zittermann A	Putting cardiovascular disease and vitamin D insufficiency into perspective.	The British journal of nutrition	2005	71
17161262	5972	Rossi GP	A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.	Journal of the American College of Cardiology	2006	107
17942703	5972	Bodyak N	Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals.	Proceedings of the National Academy of Sciences of the United States of America	2007	72
18256393	5972	Gaede P	Effect of a multifactorial intervention on mortality in type 2 diabetes.	The New England journal of medicine	2008	502
19153265	5972	Solomon SD	Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.	Circulation	2009	52
19289633	5972	B√∂ger RH	Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.	Circulation	2009	61
19874988	5972	Triposkiadis F	The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.	Journal of the American College of Cardiology	2009	117
20515678	5972	Tomaschitz A	Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study.	Clinica chimica acta; international journal of clinical chemistry	2010	43
22859525	5972	de Man FS	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension.	American journal of respiratory and critical care medicine	2012	35
23121378	5972	Parving HH	Cardiorenal end points in a trial of aliskiren for type 2 diabetes.	The New England journal of medicine	2012	133
23358488	5972	Makani H	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.	BMJ	2013	26
23478743	5972	Gheorghiade M	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.	JAMA	2013	30
23558162	5972	He FJ	Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials.	BMJ	2013	123
23633321	5972	He FJ	Effect of longer-term modest salt reduction on blood pressure.	The Cochrane database of systematic reviews	2013	35
23753408	5972	Savard S	Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study.	Hypertension	2013	33
24204003	5972	McMahon EJ	A randomized trial of dietary sodium restriction in CKD.	Journal of the American Society of Nephrology 	2013	36
25001649	5972	Iantorno M	Obesity, inflammation and endothelial dysfunction.	Journal of biological regulators and homeostatic agents	2014	23
25595565	5972	Goicoechea M	Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.	American journal of kidney diseases 	2015	31
25801871	5972	Pilz S	Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial.	Hypertension	2015	21
7733127	6240	Krahn AD	The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.	The American journal of medicine	1995	204
11874924	6240	van Dam RM	Dietary fat and meat intake in relation to risk of type 2 diabetes in men.	Diabetes care	2002	112
16620828	6240	Heald CL	Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review.	Atherosclerosis	2006	76
17258085	6240	Gami AS	Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.	Journal of the American College of Cardiology	2007	306
19951276	6240	Burra P	Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry).	American journal of transplantation 	2010	41
20191515	6240	Kim SY	Hyperuricemia and coronary heart disease: a systematic review and meta-analysis.	Arthritis care and research	2010	102
26324537	6240	Udell JA	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.	European heart journal	2016	17
11157710	6262	Laitinen PJ	Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia.	Circulation	2001	112
15322274	6262	Jiang D	RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR).	Proceedings of the National Academy of Sciences of the United States of America	2004	119
20056922	6262	Neef S	CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation.	Circulation research	2010	85
22174035	6262	Jung CB	Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.	EMBO molecular medicine	2012	90
22178870	6262	Fatima A	In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells.	Cellular physiology and biochemistry 	2011	59
22456474	6262	Voigt N	Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation.	Circulation	2012	106
22749309	6262	Itzhaki I	Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.	Journal of the American College of Cardiology	2012	60
22962621	6262	Kujala K	Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.	PloS one	2012	35
24563457	6262	Hwang HS	Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.	Circulation research	2014	23
7651517	6331	Bennett PB	Molecular mechanism for an inherited cardiac arrhythmia.	Nature	1995	195
15671429	6331	Olson TM	Sodium channel mutations and susceptibility to heart failure and atrial fibrillation.	JAMA	2005	112
17060380	6331	Vatta M	Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.	Circulation	2006	137
18662191	6331	Moss AJ	Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.	Journal of cardiovascular electrophysiology	2008	53
20091048	6331	Amin AS	Cardiac sodium channelopathies.	Pflugers Archiv 	2010	45
20488304	6331	Sossalla S	Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.	Journal of the American College of Cardiology	2010	53
21347284	6331	Smith JG	Genome-wide association studies of the PR interval in African Americans.	PLoS genetics	2011	41
22514276	6331	Ashpole NM	Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites.	The Journal of biological chemistry	2012	53
23123192	6331	Shy D	Cardiac sodium channel NaV1.5 distribution in myocytes via interacting proteins: the multiple pool model.	Biochimica et biophysica acta	2013	25
2466335	6401	Bevilacqua MP	Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins.	Science	1989	347
22771675	6401	Eirin A	Inflammatory and injury signals released from the post-stenotic human kidney.	European heart journal	2013	35
22310849	6524	Ferrannini E	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.	Nature reviews. Endocrinology	2012	41
23895803	6524	Neal B	Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.	American heart journal	2013	60
24475922	6524	Cherney DZ	The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.	Cardiovascular diabetology	2014	43
24631482	6524	Oliva RV	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.	Journal of the American Society of Hypertension 	2014	33
24766495	6524	Liakos A	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.	Diabetes, obesity and metabolism	2014	28
25341005	6524	Vallon V	The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.	Annual review of medicine	2015	18
25488697	6524	Scheen AJ	Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.	Drugs	2015	22
26378978	6524	Zinman B	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.	The New England journal of medicine	2015	305
26580237	6524	Watts NB	Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.	The Journal of clinical endocrinology and metabolism	2016	20
26895767	6524	Sonesson C	Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.	Cardiovascular diabetology	2016	19
27208375	6524	Abdul-Ghani M	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.	Diabetes care	2016	23
27289126	6524	Ferrannini E	CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.	Diabetes care	2016	24
27470878	6524	Heerspink HJ	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.	Circulation	2016	17
11489934	7137	Kehat I	Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes.	The Journal of clinical investigation	2001	298
18445579	7137	Zabrouskov V	Unraveling molecular complexity of phosphorylated human cardiac troponin I by top down electron capture dissociation/electron transfer dissociation mass spectrometry.	Molecular and cellular proteomics 	2008	55
19188504	7137	Hoole SP	Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial.	Circulation	2009	79
19372185	7137	Kuhn E	Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry.	Clinical chemistry	2009	72
20495811	7137	Thielmann M	Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest.	Basic research in cardiology	2010	57
21751783	7137	Zhang J	Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.	Journal of proteome research	2011	50
21965555	7137	Apple FS	Analytical characteristics of high-sensitivity cardiac troponin assays.	Clinical chemistry	2012	68
23953384	7137	Thielmann M	Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial.	Lancet	2013	84
24053180	7137	Wang F	Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis.	Journal of translational medicine	2013	26
24829362	7137	Chin CW	High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis.	European heart journal	2014	25
17698733	7139	Latini R	Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.	Circulation	2007	76
19357245	7139	Burton JO	Hemodialysis-induced cardiac injury: determinants and associated outcomes.	Clinical journal of the American Society of Nephrology 	2009	96
21078811	7139	deFilippi CR	Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.	JAMA	2010	135
21139111	7139	de Lemos JA	Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.	JAMA	2010	159
22370326	7139	Lipshultz SE	Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.	Journal of clinical oncology 	2012	40
24930130	7139	Burridge PW	Chemically defined generation of human cardiomyocytes.	Nature methods	2014	137
7569978	7273	Labeit S	Titins: giant proteins in charge of muscle ultrastructure and elasticity.	Science	1995	221
10573426	7273	Marszalek PE	Mechanical unfolding intermediates in titin modules.	Nature	1999	183
11149943	7273	Oberhauser AF	Stepwise unfolding of titin under force-clamp atomic force microscopy.	Proceedings of the National Academy of Sciences of the United States of America	2001	89
11717165	7273	Bang ML	The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system.	Circulation research	2001	146
12198551	7273	Li H	Reverse engineering of the giant muscle protein titin.	Nature	2002	131
15238456	7273	Nagueh SF	Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy.	Circulation	2004	96
15345656	7273	Makarenko I	Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts.	Circulation research	2004	74
17475230	7273	Linke WA	Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction.	Cardiovascular research	2008	93
19179657	7273	Borb√©ly A	Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium.	Circulation research	2009	71
19962384	7273	Barefield D	Phosphorylation and function of cardiac myosin binding protein-C in health and disease.	Journal of molecular and cellular cardiology	2010	89
22335739	7273	Herman DS	Truncations of titin causing dilated cardiomyopathy.	The New England journal of medicine	2012	183
23975875	7273	Ceyhan-Birsoy O	Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy.	Neurology	2013	27
24056688	7273	Rain S	Right ventricular diastolic impairment in patients with pulmonary arterial hypertension.	Circulation	2013	36
24503780	7273	Pugh TJ	The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing.	Genetics in medicine 	2014	35
24625729	7273	Linke WA	Gigantic business: titin properties and function through thick and thin.	Circulation research	2014	44
24630725	7273	Alegre-Cebollada J	S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding.	Cell	2014	31
25589632	7273	Roberts AM	Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease.	Science translational medicine	2015	35
26315439	7273	Hinson JT	HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy.	Science	2015	50
26735901	7273	Ware JS	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies.	The New England journal of medicine	2016	12
1791831	7422	Houck KA	The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.	Molecular endocrinology	1991	199
2479987	7422	Keck PJ	Vascular permeability factor, an endothelial cell mitogen related to PDGF.	Science	1989	279
7526212	7422	Aiello LP	Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.	The New England journal of medicine	1994	569
7673356	7422	Roberts WG	Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.	Journal of cell science	1995	170
8167412	7422	Park JE	The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.	Molecular biology of the cell	1993	181
8837607	7422	Gabrilovich DI	Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.	Nature medicine	1996	271
9012841	7422	M√∂hle R	Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.	Proceedings of the National Academy of Sciences of the United States of America	1997	110
9377574	7422	Presta LG	Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.	Cancer research	1997	287
9529250	7422	Soker S	Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.	Cell	1998	486
9707121	7422	Flore O	Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.	Nature	1998	109
9916127	7422	Benjamin LE	Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.	The Journal of clinical investigation	1999	225
10406801	7422	Asahara T	VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.	The EMBO journal	1999	299
10662790	7422	Yang TY	Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma.	The Journal of experimental medicine	2000	94
12124351	7422	Bates DO	VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.	Cancer research	2002	143
12177445	7422	Holash J	VEGF-Trap: a VEGF blocker with potent antitumor effects.	Proceedings of the National Academy of Sciences of the United States of America	2002	331
12642354	7422	Henry TD	The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.	Circulation	2003	161
14557356	7422	Britten MB	Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.	Circulation	2003	84
14993122	7422	Rehman J	Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.	Circulation	2004	362
16172288	7422	Khurana R	Role of angiogenesis in cardiovascular disease: a critical appraisal.	Circulation	2005	79
16490250	7422	Leach JK	Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration.	Biomaterials	2006	67
16828580	7422	Borzychowski AM	Inflammation and pre-eclampsia.	Seminars in fetal and neonatal medicine	2006	89
17475821	7422	Lindenmeyer MT	Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.	Journal of the American Society of Nephrology 	2007	69
17533168	7422	Rigau V	Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy.	Brain 	2007	69
17591953	7422	Nishijima K	Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.	The American journal of pathology	2007	170
17636120	7422	Sayed N	Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
19150949	7422	Izzedine H	Management of hypertension in angiogenesis inhibitor-treated patients.	Annals of oncology 	2009	57
19234476	7422	Augustin HG	Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.	Nature reviews. Molecular cell biology	2009	292
19581909	7422	Chen HX	Adverse effects of anticancer agents that target the VEGF pathway.	Nature reviews. Clinical oncology	2009	90
20156114	7422	Ranpura V	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.	Acta oncologica	2010	43
20351338	7422	Maitland ML	Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.	Journal of the National Cancer Institute	2010	53
20501804	7422	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	49
21092406	7422	Crespo-Diaz R	Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability.	Cell transplantation	2011	44
21167939	7422	Fidler IJ	The role of the organ microenvironment in brain metastasis.	Seminars in cancer biology	2011	63
21239704	7422	Stratman AN	VEGF and FGF prime vascular tube morphogenesis and sprouting directed by hematopoietic stem cell cytokines.	Blood	2011	38
21323540	7422	Mintz-Hittner HA	Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.	The New England journal of medicine	2011	124
21441136	7422	Li J	Orai1 and CRAC channel dependence of VEGF-activated Ca2+ entry and endothelial tube formation.	Circulation research	2011	51
21527770	7422	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	115
21593862	7422	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	810
21732485	7422	Horie N	Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair.	Stem cells	2011	61
22212972	7422	Stewart MW	The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.	Mayo Clinic proceedings	2012	33
22399811	7422	dela Paz NG	Role of shear-stress-induced VEGF expression in endothelial cell survival.	Journal of cell science	2012	37
23108136	7422	Terme M	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.	Cancer research	2013	61
23856679	7422	Taimeh Z	Vascular endothelial growth factor in heart failure.	Nature reviews. Cardiology	2013	29
24013197	7422	Zangi L	Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.	Nature biotechnology	2013	70
24949972	7422	Eswarappa SM	Programmed translational readthrough generates antiangiogenic VEGF-Ax.	Cell	2014	40
25220133	7422	Moja L	Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.	The Cochrane database of systematic reviews	2014	27
25342124	7422	Virgili G	Anti-vascular endothelial growth factor for diabetic macular oedema.	The Cochrane database of systematic reviews	2014	30
25896459	7422	Ishibazawa A	Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study.	American journal of ophthalmology	2015	50
26113213	7422	Nazari H	Stem cell based therapies for age-related macular degeneration: The promises and the challenges.	Progress in retinal and eye research	2015	19
26137590	7422	Premer C	Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells.	EBioMedicine	2015	20
15731492	7941	Zalewski A	Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.	Arteriosclerosis, thrombosis, and vascular biology	2005	86
24415784	7941	Eckard AR	Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.	The Journal of infectious diseases	2014	33
24678955	7941	STABILITY Investigators.	Darapladib for preventing ischemic events in stable coronary heart disease.	The New England journal of medicine	2014	64
25173516	7941	O'Donoghue ML	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.	JAMA	2014	44
26424461	7941	Lo J	Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.	The lancet. HIV	2015	27
14633152	8074	Larsson T	Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.	Kidney international	2003	147
19181315	8074	Mirza MA	Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community.	Atherosclerosis	2009	90
19395730	8074	Jean G	High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.	Nephrology, dialysis, transplantation 	2009	73
19524924	8074	Mirza MA	Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.	Atherosclerosis	2009	85
20176609	8074	Nasrallah MM	Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients.	Nephrology, dialysis, transplantation 	2010	43
20507943	8074	Wolf M	Forging forward with 10 burning questions on FGF23 in kidney disease.	Journal of the American Society of Nephrology 	2010	67
20525642	8074	Seiler S	FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.	Nephrology, dialysis, transplantation 	2010	47
20613714	8074	Yilmaz MI	FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.	Kidney international	2010	41
20966399	8074	Mirza MA	Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.	Arteriosclerosis, thrombosis, and vascular biology	2011	39
21436289	8074	Wolf M	Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.	Journal of the American Society of Nephrology 	2011	65
21903574	8074	Kendrick J	FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.	Journal of the American Society of Nephrology 	2011	120
22034506	8074	Guti√©rrez OM	Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.	Clinical journal of the American Society of Nephrology 	2011	36
22492635	8074	Lim K	Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.	Circulation	2012	99
22622492	8074	Wolf M	Update on fibroblast growth factor 23 in chronic kidney disease.	Kidney international	2012	59
22703926	8074	Ix JH	Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).	Journal of the American College of Cardiology	2012	82
22951890	8074	√Ñrnl√∂v J	Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.	Kidney international	2013	36
23389416	8074	Scialla JJ	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.	Kidney international	2013	54
24158986	8074	Scialla JJ	Fibroblast growth factor-23 and cardiovascular events in CKD.	Journal of the American Society of Nephrology 	2014	63
24686452	8074	Scialla JJ	Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.	Nature reviews. Nephrology	2014	25
25967123	8074	Isakova T	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.	Journal of the American Society of Nephrology 	2015	17
26059012	8074	Moe SM	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.	Circulation	2015	23
20189712	8654	Hatzimouratidis K	Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.	European urology	2010	103
21036891	8654	Guazzi M	PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.	Circulation. Heart failure	2011	74
8432214	8991	Stamler J	Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.	Diabetes care	1993	454
11126342	8991	Savva SC	Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index.	International journal of obesity and related metabolic disorders 	2000	115
10982546	9370	Ouchi N	Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.	Circulation	2000	273
11752030	9370	Zoccali C	Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.	Journal of the American Society of Nephrology 	2002	91
12860835	9370	Ouchi N	Association of hypoadiponectinemia with impaired vasoreactivity.	Hypertension	2003	83
14557259	9370	Ouchi N	Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells.	The Journal of biological chemistry	2004	194
14752031	9370	Kobayashi H	Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin.	Circulation research	2004	125
15096450	9370	Kumada M	Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages.	Circulation	2004	108
15181024	9370	Goldstein BJ	Adiponectin: A novel adipokine linking adipocytes and vascular function.	The Journal of clinical endocrinology and metabolism	2004	105
16464169	9370	Okamoto Y	Adiponectin: a key adipocytokine in metabolic syndrome.	Clinical science	2006	86
17224929	9370	C√¥t√© M	Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.	International journal of obesity	2007	67
17227956	9370	Potenza MA	EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR.	American journal of physiology. Endocrinology and metabolism	2007	59
17374708	9370	Anderson PD	Innate immunity modulates adipokines in humans.	The Journal of clinical endocrinology and metabolism	2007	56
17495599	9370	Lara-Castro C	Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.	Current opinion in lipidology	2007	61
17540190	9370	Sacks HS	Human epicardial adipose tissue: a review.	American heart journal	2007	141
18061654	9370	Fantuzzi G	Adiponectin and inflammation: consensus and controversy.	The Journal of allergy and clinical immunology	2008	79
18265479	9370	Barb D	Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.	The American journal of clinical nutrition	2007	97
19756488	9370	Finucane FM	Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals.	Diabetologia	2009	60
20018283	9370	Heid IM	Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals.	Atherosclerosis	2010	57
20028977	9370	Ohashi K	Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype.	The Journal of biological chemistry	2010	131
22226221	9370	Wronska A	Structural and biochemical characteristics of various white adipose tissue depots.	Acta physiologica	2012	59
22547160	9370	Dalamaga M	The role of adiponectin in cancer: a review of current evidence.	Endocrine reviews	2012	85
23781214	9370	Kwon H	Adipokines mediate inflammation and insulin resistance.	Frontiers in endocrinology	2013	62
25110685	9370	Nigro E	New insight into adiponectin role in obesity and obesity-related diseases.	BioMed research international	2014	34
26978208	9370	Tyrrell J	Genetic Evidence for Causal Relationships Between Maternal Obesity-Related Traits and Birth Weight.	JAMA	2016	19
11997274	9933	Marchioli R	Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.	Circulation	2002	164
12583947	9933	Thies F	Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.	Lancet	2003	93
19244379	9933	Harris WS	Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids.	The Journal of nutrition	2009	50
19660687	9933	Lavie CJ	Omega-3 polyunsaturated fatty acids and cardiovascular diseases.	Journal of the American College of Cardiology	2009	83
22279134	9933	Mozaffarian D	(n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?	The Journal of nutrition	2012	57
22282329	9933	Wu JH	Association of plasma phospholipid long-chain œâ-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study.	Circulation	2012	41
23128104	9933	Mozaffarian D	Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.	JAMA	2012	32
23546563	9933	Mozaffarian D	Plasma phospholipid long-chain œâ-3 fatty acids and total and cause-specific mortality in older adults: a cohort study.	Annals of internal medicine	2013	40
24351702	9933	de Oliveira Otto MC	Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis.	Journal of the American Heart Association	2013	27
26068959	9933	Hooper L	Reduction in saturated fat intake for cardiovascular disease.	The Cochrane database of systematic reviews	2015	30
14657344	10021	Stieber J	The hyperpolarization-activated channel HCN4 is required for the generation of pacemaker action potentials in the embryonic heart.	Proceedings of the National Academy of Sciences of the United States of America	2003	89
17478540	10021	Gaborit N	Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.	The Journal of physiology	2007	111
23974038	10021	Sp√§ter D	A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells.	Nature cell biology	2013	37
15867843	10135	Fantuzzi G	Adipose tissue, adipokines, and inflammation.	The Journal of allergy and clinical immunology	2005	392
16186392	10135	Berndt J	Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.	Diabetes	2005	87
16311215	10135	Koerner A	Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come.	Best practice and research. Clinical endocrinology and metabolism	2005	73
16496121	10135	Curat CA	Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.	Diabetologia	2006	89
18093861	10135	Antuna-Puente B	Adipokines: the missing link between insulin resistance and obesity.	Diabetes and metabolism	2008	108
20068143	10135	de Kreutzenberg SV	Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms.	Diabetes	2010	56
20145358	10135	Spiroglou SG	Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.	Journal of atherosclerosis and thrombosis	2010	53
20847813	10135	Wang Z	Inflammation, a link between obesity and cardiovascular disease.	Mediators of inflammation	2010	67
8181668	10242	Albelda SM	Adhesion molecules and inflammatory injury.	FASEB journal 	1994	131
8381058	10242	Ungerer M	Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.	Circulation	1993	143
9918525	10242	Bowling N	Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart.	Circulation	1999	99
15655528	10242	Baker JG	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.	British journal of pharmacology	2005	92
12176889	10365	Dekker RJ	Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Kr√ºppel-like factor (KLF2).	Blood	2002	147
15136591	10365	SenBanerjee S	KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation.	The Journal of experimental medicine	2004	159
16049344	10365	Dekker RJ	Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes.	The American journal of pathology	2005	68
16341264	10365	Parmar KM	Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2.	The Journal of clinical investigation	2006	166
16455954	10365	Dekker RJ	KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.	Blood	2006	84
16617118	10365	Das H	Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes.	Proceedings of the National Academy of Sciences of the United States of America	2006	63
17913848	10365	Hastings NE	Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming.	American journal of physiology. Cell physiology	2007	63
19968965	10365	Villarreal G Jr	Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular endothelial cells.	Biochemical and biophysical research communications	2010	50
21768538	10365	Wu W	Flow-Dependent Regulation of Kruppel-Like Factor 2 Is Mediated by MicroRNA-92a.	Circulation	2011	73
22267480	10365	Fang Y	Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium.	Arteriosclerosis, thrombosis, and vascular biology	2012	69
27027284	10365	Zhou Z	Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.	Nature	2016	13
12563316	10544	Cheng T	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.	Nature medicine	2003	145
12970121	10544	Esmon CT	The protein C pathway.	Chest	2003	112
15710622	10544	Finigan JH	Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.	The Journal of biological chemistry	2005	131
23741007	10544	Moxon CA	Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children.	Blood	2013	64
12807871	10891	Tiraby C	Acquirement of brown fat cell features by human white adipocytes.	The Journal of biological chemistry	2003	97
15716268	10891	Nemoto S	SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}.	The Journal of biological chemistry	2005	284
15914121	10891	Valle I	PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells.	Cardiovascular research	2005	115
17466956	10891	Murphy E	Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury.	Cardiovascular research	2007	56
19061896	10891	Sihag S	PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart.	Journal of molecular and cellular cardiology	2009	57
19853062	10891	Spindler SR	Caloric restriction: from soup to nuts.	Ageing research reviews	2010	58
20371735	10891	Lira VA	PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity.	American journal of physiology. Endocrinology and metabolism	2010	60
21775390	10891	Bouitbir J	Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1.	European heart journal	2012	34
23104101	10891	Morris BJ	Seven sirtuins for seven deadly diseases of aging.	Free radical biology and medicine	2013	61
24411942	10891	Roberts LD	Œ≤-Aminoisobutyric acid induces browning of white fat and hepatic Œ≤-oxidation and is inversely correlated with cardiometabolic risk factors.	Cell metabolism	2014	64
24506866	10891	Sawada N	Endothelial PGC-1Œ± mediates vascular dysfunction in diabetes.	Cell metabolism	2014	27
25863249	10891	Diebold I	BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.	Cell metabolism	2015	18
9613910	22796	Downs JR	Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.	JAMA	1998	444
12479764	22796	ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.	Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).	JAMA	2002	175
14600185	22796	Li S	Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study.	JAMA	2003	144
16316964	22796	Pischon T	Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.	Circulation	2005	74
17030687	22796	Kastelein JJ	Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.	Circulation	2006	62
18317847	22796	Schmittdiel JA	Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification.	Journal of general internal medicine	2008	74
21392724	22796	Otvos JD	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number.	Journal of clinical lipidology	2011	45
22453571	22796	Boekholdt SM	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.	JAMA	2012	87
22811413	22796	Lambert G	The PCSK9 decade.	Journal of lipid research	2012	45
23141813	22796	Giugliano RP	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.	Lancet	2012	56
24002278	22796	Thom S	Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.	JAMA	2013	32
24255061	22796	Koren MJ	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.	Circulation	2014	34
24345402	22796	Mora S	Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events.	Circulation	2014	20
24468148	22796	Gylling H	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease.	Atherosclerosis	2014	33
24474739	22796	Holmes MV	Mendelian randomization of blood lipids for coronary heart disease.	European heart journal	2015	40
24639424	22796	Ray KK	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.	European heart journal	2014	35
24958078	22796	Dadu RT	Lipid lowering with PCSK9 inhibitors.	Nature reviews. Cardiology	2014	30
25440796	22796	Schwartz GG	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.	American heart journal	2014	28
25467842	22796	Chen L	Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis.	Metabolism	2015	16
26227186	22796	Tsujita K	Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.	Journal of the American College of Cardiology	2015	16
26687696	22796	Moriarty PM	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.	Journal of clinical lipidology	2015	21
15768047	23411	Bordone L	Calorie restriction, SIRT1 and metabolism: understanding longevity.	Nature reviews. Molecular cell biology	2005	260
17916362	23411	Ota H	Sirt1 modulates premature senescence-like phenotype in human endothelial cells.	Journal of molecular and cellular cardiology	2007	95
18641460	23411	Potente M	Emerging roles of SIRT1 in vascular endothelial homeostasis.	Cell cycle	2008	53
19286634	23411	Orimo M	Protective role of SIRT1 in diabetic vascular dysfunction.	Arteriosclerosis, thrombosis, and vascular biology	2009	47
20027304	23411	Nasrin N	JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.	PloS one	2009	93
20078221	23411	Haigis MC	Mammalian sirtuins: biological insights and disease relevance.	Annual review of pathology	2010	460
20089851	23411	Tanno M	Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure.	The Journal of biological chemistry	2010	79
20627091	23411	Ito T	MicroRNA-34a regulation of endothelial senescence.	Biochemical and biophysical research communications	2010	69
21746786	23411	Donato AJ	SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans.	The Journal of physiology	2011	40
21778425	23411	Zhou S	Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction.	Circulation research	2011	44
22455351	23411	Chen AF	Free radical biology of the cardiovascular system.	Clinical science	2012	30
22479251	23411	Yamakuchi M	MicroRNA Regulation of SIRT1.	Frontiers in physiology	2012	38
23878368	23411	Gliemann L	Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men.	The Journal of physiology	2013	40
23932046	23411	Palomer X	An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.	International journal of cardiology	2013	30
24314860	23411	Wang S	Novel insights of dietary polyphenols and obesity.	The Journal of nutritional biochemistry	2014	66
24439680	23411	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	77
25315298	23411	Kulkarni SS	The molecular targets of resveratrol.	Biochimica et biophysica acta	2015	33
25451966	23411	Zordoky BN	Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.	Biochimica et biophysica acta	2015	22
25538153	23411	Planavila A	Fibroblast growth factor 21 protects the heart from oxidative stress.	Cardiovascular research	2015	21
19118249	64805	Marcucci R	Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.	Circulation	2009	53
19717846	64805	Wallentin L	Ticagrelor versus clopidogrel in patients with acute coronary syndromes.	The New England journal of medicine	2009	431
20079528	64805	Cannon CP	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.	Lancet	2010	50
20828644	64805	Bonello L	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.	Journal of the American College of Cardiology	2010	90
23121439	64805	Collet JP	Bedside monitoring to adjust antiplatelet therapy for coronary stenting.	The New England journal of medicine	2012	60
24076493	64805	Tantry US	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.	Journal of the American College of Cardiology	2013	57
25773268	64805	Bonaca MP	Long-term use of ticagrelor in patients with prior myocardial infarction.	The New England journal of medicine	2015	51
21841020	79784	Weiss EP	Caloric restriction: powerful protection for the aging heart and vasculature.	American journal of physiology. Heart and circulatory physiology	2011	39
23798412	79784	Sommese RF	Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human Œ≤-cardiac myosin motor function.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
25552695	79784	Moss RL	Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium.	Circulation research	2015	26
20452521	116519	Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.	Lancet	2010	100
25487149	116519	Do R	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.	Nature	2015	85
17435765	255738	Cunningham D	Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.	Nature structural and molecular biology	2007	91
17452316	255738	Zhang DW	Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.	The Journal of biological chemistry	2007	136
18033751	255738	Careskey HE	Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.	Journal of lipid research	2008	60
19351729	255738	Lakoski SG	Genetic and metabolic determinants of plasma PCSK9 levels.	The Journal of clinical endocrinology and metabolism	2009	68
22331829	255738	Chasman DI	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.	Circulation. Cardiovascular genetics	2012	40
23884353	255738	Desai NR	AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.	Circulation	2013	32
24014831	255738	Stein EA	Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.	Circulation	2013	41
24509273	255738	Raal FJ	Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.	Journal of the American College of Cardiology	2014	43
24585268	255738	Sjouke B	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.	European heart journal	2015	30
24625727	255738	Seidah NG	PCSK9: a key modulator of cardiovascular health.	Circulation research	2014	53
24678979	255738	Blom DJ	A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.	The New England journal of medicine	2014	76
24694531	255738	Stroes E	Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.	Journal of the American College of Cardiology	2014	70
24825642	255738	Robinson JG	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.	JAMA	2014	57
25037695	255738	Roth EM	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.	International journal of cardiology	2014	38
25070550	255738	Rashid S	Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.	Circulation	2014	23
25282519	255738	Raal FJ	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.	Lancet	2015	66
25282520	255738	Raal FJ	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.	Lancet	2015	66
25773378	255738	Robinson JG	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.	The New England journal of medicine	2015	149
25773607	255738	Sabatine MS	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.	The New England journal of medicine	2015	131
25778403	255738	Romagnuolo R	Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.	The Journal of biological chemistry	2015	27
25784512	255738	Ballantyne CM	Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.	The American journal of cardiology	2015	23
25915661	255738	Navarese EP	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.	Annals of internal medicine	2015	45
26027630	255738	Kereiakes DJ	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.	American heart journal	2015	28
26030325	255738	Bays H	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.	The Journal of clinical endocrinology and metabolism	2015	24
26578202	255738	Lipinski MJ	The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.	European heart journal	2016	18
26718096	255738	Banach M	Lipids, blood pressure and kidney update 2015.	Lipids in health and disease	2015	16
26920601	255738	Sabatine MS	Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.	American heart journal	2016	14
27050191	255738	Khera AV	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.	Journal of the American College of Cardiology	2016	16
27701660	255738	Lotta LA	Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.	JAMA	2016	17
27846344	255738	Nicholls SJ	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.	JAMA	2016	19
27959767	255738	Ference BA	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.	The New England journal of medicine	2016	15
19195618	286205	Patel MR	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography.	Journal of the American College of Cardiology	2009	59
20233780	286205	Hiratzka LF	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine.	Circulation	2010	206
20359588	286205	Hiratzka LF	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine.	Journal of the American College of Cardiology	2010	115
21338862	286205	American College of Cardiology Foundation Appropriate Use Criteria Task Force.	ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians.	Journal of the American Society of Echocardiography 	2011	64
22296741	286205	Patel MR	ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography.	Journal of the American College of Cardiology	2012	66
23166210	286205	Fihn SD	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.	Circulation	2012	33
23166211	286205	Fihn SD	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.	Circulation	2012	82
23182125	286205	Fihn SD	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.	Journal of the American College of Cardiology	2012	148
24355759	286205	Wolk MJ	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons.	Journal of the American College of Cardiology	2014	50
25070666	286205	Fihn SD	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.	Circulation	2014	34
26490017	286205	Levine GN	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.	Circulation	2016	16
27026020	286205	Levine GN	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.	Circulation	2016	23
21294650	100506658	Carrano A	Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.	Antioxidants and redox signaling	2011	45
21909359	100506658	Biron KE	Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease.	PloS one	2011	49
22197032	100506658	Xu R	HIV-1 Tat protein increases the permeability of brain endothelial cells by both inhibiting occludin expression and cleaving occludin via matrix metalloproteinase-9.	Brain research	2012	37
